



Published in final edited form as:

*Med Res Rev.* 2001 July ; 21(4): 245–273.

## The Ubiquitin-Proteasome Pathway and Proteasome Inhibitors

Jayhyuk Myung<sup>1</sup>, Kyung Bo Kim<sup>1</sup>, and Craig M. Crews<sup>1,2</sup>

<sup>1</sup>*Department of Molecular, Cellular, and Developmental Biology, Yale University, New Haven, Connecticut 06520-8103*

<sup>2</sup>*Department of Pharmacology, Yale University, New Haven, Connecticut 06520-8103*

### Abstract

The ubiquitin-proteasome pathway has emerged as a central player in the regulation of several diverse cellular processes. Here, we describe the important components of this complex biochemical machinery as well as several important cellular substrates targeted by this pathway and examples of human diseases resulting from defects in various components of the ubiquitin-proteasome pathway. In addition, this review covers the chemistry of synthetic and natural proteasome inhibitors, emphasizing their mode of actions toward the 20S proteasome. Given the importance of proteasome-mediated protein degradation in various intracellular processes, inhibitors of this pathway will continue to serve as both molecular probes of major cellular networks as well as potential therapeutic agents for various human diseases.

### Keywords

ubiquitin-proteasome pathway; protein degradation; proteasome inhibitor; natural product

## 1. INTRODUCTION

The integrity of cellular processes depends upon the proper balance of different proteins. Among the possible ways to control the activities of such molecules, controlling protein half-life itself by destruction has emerged as a major cellular regulatory mechanism. In cells, there are two major destruction pathways involving either a collection of proteolytic enzymes within the lysosome or the multicatalytic proteolytic core of the ubiquitin-proteasome pathway. This review focuses this latter system.

The majority of proteins that are destined for degradation are marked by the covalent attachment of multiple ubiquitin molecules, which provide a recognition signal for the 26S proteasome. Since the ubiquitin-proteasome pathway degrades a wide range of protein substrates with exquisite specificity, nature has developed an ingenious way to divide this complex biochemical machinery into two discrete and successive steps: first, a specific recognition process, employing the ubiquitin conjugation cascade, and secondly, an indiscriminate destruction process, mediated by the proteolytic proteasome core. The ubiquitin conjugation cascade uses a highly modular approach that can be used in different combinations for different purposes. Specifically, three different sets of enzymes i.e., E1, E2, and E3, shuttle ubiquitin and eventually link ubiquitin to the protein substrate. Different combinations of E2 or E3 or both recognize each substrate's unique degradation signal, thereby conferring exquisite specificity for ubiquitination of diverse protein substrates. Ultimately, most ubiquitinated proteins are recognized by the 26S proteasome, unfolded, and threaded into the

20S proteolytic chamber in an ATP-dependent manner. The second, indiscriminate proteolytic step provides directionality for a signaling pathway, i.e., once a protein is committed for degradation, there is no return, ensuring that partially degraded proteins do not interfere with biological processes.

This ATP- and ubiquitin-dependent process is responsible for intracellular activities as diverse as the removal of misfolded or aged housekeeping proteins, cell cycle regulation via cyclin degradation, and cellular immune response by antigenic peptide processing. Given the wide range of cellular substrates and processes that are controlled by the ubiquitin-proteasome pathway, the components of this pathway have become an attractive novel target for therapeutic intervention. Indeed, aberrations in this pathway have been implicated in the pathogenesis of several human diseases. Although the ubiquitin-proteasome pathway can be blocked at various steps, most inhibitors of this pathway directly target the proteolytic activities of the 20S proteasome. The number of such proteasome inhibitors is growing and their target and subunit specificities have improved in recent years, leading to their inclusion in several clinical trials. To widen the potential for the treatment of a wider range of disorders and to gain greater specificity, future efforts will undoubtedly focus on the development of inhibitors/activators that affect earlier steps of the ubiquitin-proteasome pathway, allowing selective inhibition of the destruction of specific proteins.

## 2. UBIQUITIN-PROTEASOME PATHWAY

### A. Ubiquitin Cascade System

The ubiquitin-proteasome pathway degrades diverse cellular proteins with exquisite specificity. To accomplish this, a highly modular and elaborate ubiquitination machinery is employed to recognize selectively specific substrates. Ubiquitin is composed of 76 amino acid residues and its primary sequence is highly conserved from yeast to mammals, thus resulting in essentially identical tertiary structure.<sup>1</sup> X-ray diffraction and proton NMR analyses have allowed the determination of the tertiary structure of ubiquitin,<sup>2-4</sup> revealing its highly compact and rigid nature: only the four carboxy terminal amino acid residues, including Gly-76 that is activated in an ATP-dependent manner for subsequent ubiquitin ligation with the  $\epsilon$ -amino group of an internal Lys residue of the protein substrate, are extended and unstructured. Another important residue, Lys-48, of ubiquitin is located on the surface of a Type III reverse turn, providing its  $\epsilon$ -amino group for an easy access to form an additional amide isopeptide bond to generate multi ubiquitin chains.

In the first step of the ubiquitin conjugation cascade, the carboxyl group of Gly-76 of ubiquitin is activated by ubiquitin-activating enzyme (E1). This step involves the hydrolysis of ATP to  $PP_i$  to generate an ubiquitinyl adenylate intermediate bound to an E1 enzyme. Subsequently, an active site Cys residue of E1 covalently links to ubiquitin via a high-energy thioester linkage, with the concomitant release of AMP. Following activation, activated ubiquitin is then transferred by transacylation reaction to a thiol group of an active site Cys residue of E2 (ubiquitin carrier protein or ubiquitin-conjugating enzyme). Finally, E2 shuttles ubiquitin either directly to a protein substrate by itself or in cooperation with ubiquitin-protein ligase (E3), to form an amide isopeptide bond between the carboxyl group of Gly-76 of ubiquitin and an  $\epsilon$ -amino group of the protein substrate's internal Lys residue. The last step occurs by first transferring ubiquitin from E2 to E3, which accepts ubiquitin in a similar thiol linkage and then to the protein substrate. In some cases, however, covalent linkage between E3 and ubiquitin is not observed and it appears that ubiquitin is directly transferred from E2 to the protein substrate in a ternary E2-E3-substrate complex.

Once the protein substrate is mono-ubiquitinated, a polyubiquitin chain is formed through the same ubiquitination conjugation cascade, as described above, in which the carboxyl group of

the carboxy terminal Gly-76 of ubiquitin is covalently linked to an internal Lys residue of ubiquitin that is already conjugated to the protein substrate.

It should be emphasized that the specificity of ubiquitination is largely determined by a series of E3 enzymes and E3 multiprotein complexes, each of which is specific to one or a few corresponding protein substrate(s) and of E2 enzymes, each of which is dedicated to their cognate E3 enzyme(s). As a result, different combinations of E2 and E3 enzymes allow selective tagging and degradation of specific intracellular proteins. In contrast, there is a single family of E1 that is highly conserved.

## 1. Enzymes of the Ubiquitination Cascade System

**E1 (UBIQUITIN-ACTIVATING ENZYME OR UBA):** A single E1 appears to be responsible for the activation of ubiquitin required for all modifications. In yeast, for example, only one functional UBA, UBA1 is known for its ubiquitin-activating activity.<sup>5</sup> Its deletion is lethal in yeast, as expected, and mutation of a putative active-site Cys residue abolishes E1 activity.<sup>6</sup>

**E2 (UBIQUITIN-CARRIER PROTEIN OR UBIQUITIN-CONJUGATING ENZYME OR UBC):** Many E2s have been identified, at least 13 in yeast (UBC1–13) and more than 20 in mammals,<sup>7,8</sup> reflecting their role in conferring the specificity for ubiquitination of diverse protein substrates. All E2s contain a conserved ~130 amino acid-long catalytic core sequence i.e., UBC domain. An active-site Cys residue within the UBC domain is essential since it is required to form an ubiquitin-thioester intermediate. As a result, mutation of an active-site Cys residue abolishes UBC activity.<sup>9,10</sup> E2s are subdivided on the basis of their distinct primary sequences, presumably reflecting their different specificities for their cognate E3s. For example, class I E2s, such as UBC4, UBC5, UBC7, and UBC9–13 consist exclusively of UBC domain and may require their cognate E3s for recognition of substrates, since they cannot alone transfer ubiquitin to substrates. Class II (UBC1, UBC2/RAD6, UBC3/CDC34, UBC6, and UBC8), class III (UBC6), and class IV E2s contain unique carboxy or amino terminal extensions or both that may mediate substrate specificity as well as intracellular localization.

Among the 13 known yeast E2s, only UBC3 and UBC9 are encoded by essential genes<sup>11,12</sup> and both are involved in regulating cell cycle progression. UBC3/CDC34, for example, is involved in the degradation of SIC1 CDK inhibitor, which is necessary for the G<sub>1</sub> to S phase transition, in conjunction with CDC53, SKP1, and CDC4.<sup>13,14</sup> In addition, UBC2/RAD6 is involved in DNA repair in cooperation with its cognate E3 $\alpha$ <sup>15</sup> to degrade so-called *N*-end rule protein substrates. It is generally believed that E2s together with their cognate E3s recognize specific protein substrates. Such examples and specific E3s will be described below in more detail.

**E3S (UBIQUITIN-PROTEIN LIGASES):** E3 ligases or ligase complexes recognize specific motifs in their substrate(s) and catalyze the transfer of ubiquitin directly or indirectly from a thioester intermediate from their cognate E2 to form an amide isopeptide bond between protein substrate and ubiquitin.<sup>16,17</sup> In general, there are a few possible mechanisms for recognition of protein substrates by the different E3s. For example, some substrates carry degradation signals that are constitutively active, whereas other substrates require a covalent modification of the sequence motif, such as phosphorylation. Conversely, E3s themselves can be altered or bound with an ancillary protein to recognize a specific subset of substrates. Various examples of such regulation and different families of E3 ligases are described below.

*i. N-end rule family:* E3 $\alpha$  was the first identified E3 ligase, which was originally defined as a third enzyme component, in addition to E1 and E2, of the ubiquitin cascade system.<sup>18</sup> Yeast

homolog to E3 $\alpha$ , UBR1, was also found.<sup>19</sup> A specific E2, UBC2/RAD6 is shown to interact with its cognate UBR1,<sup>15,20–22</sup> and activated ubiquitin is believed to be transferred directly to the substrate in a ternary E2–E3–substrate complex.<sup>16</sup>

E3 $\alpha$ /UBR1 is a large ~200 kDa protein with several distinct functional domains. It has two distinct and independent sites that recognize *N*-end rule substrates through their amino terminal residues — a type-1 site that recognizes basic residues, such as Arg, Lys, and His, and a type-2 site that recognizes bulky hydrophobic residues, such as Leu, Ile, Phe, Trp, and Tyr.<sup>23,24</sup> It also contains a third substrate-binding site that recognizes a non-*N*-end rule substrate, such as GPA1 and CUP9.<sup>25,26</sup> Interestingly, binding of type-1 or type-2 dipeptides to their respective sites allosterically stimulates association of CUP9 with UBR1,<sup>27</sup> suggesting yet another mechanism to control the activity of E3 ligase.

Careful analysis of interaction with E3 UBR1 and its cognate E2 ligase UBC2 revealed that binding is mediated largely between the *basic residue-rich* (BRR) domain of UBR1 and the polyacidic carboxy terminal tail of UBC2.<sup>28</sup> Interestingly, a RING-H2 finger motif, which was found near BRR domain, is also essential for ubiquitination and the ultimate degradation of *N*-end rule substrates, though this domain does not appear to involve in binding to both UBC2 and substrates. The exact nature of the role of a RING finger motif in UBR1 awaits further examination, yet it should be noted that a RING finger motif has become one of most exciting new motifs found in other E3s, as described below.

**ii. Hect (homologous to E6-AP carboxy terminus) domain family:** The Hect class of E3s possess an approximately 350 amino acid-long carboxy terminal sequence, which is highly homologous to that of E6-AP.<sup>29</sup> E6-AP was initially identified as an associating protein to E6 oncoprotein produced by human papillomavirus.<sup>30</sup> The E6-AP and E6 complex was later found to mediate ubiquitination of p53, which ultimately is degraded by the ubiquitin-proteasome pathway. Interestingly, E6-AP was found to promote ubiquitination of other cellular substrates in the absence of E6,<sup>31,32</sup> suggesting its role as an E3 ubiquitin protein ligase. To date, at least 20 members of Hect proteins in human have been identified.<sup>33</sup> Unlike other classes of E3s, Hect E3s form an ubiquitin-thioester intermediate via a conserved active-site Cys residue within the Hect domain and directly catalyze substrate ubiquitination.<sup>19,34</sup>

In contrast to the carboxy terminus, the amino terminal sequence of Hect E3s is highly variable and contains the primary determinants for recognition of specific substrates.<sup>29,35</sup> For example, WW domains in the variable amino terminal extension of both yeast RSP5 and its mammalian homolog Nedd4 bind to the PPxY sequences of their cellular substrates, the yeast RNA polymerase II (Rpb1) and the human epithelial sodium channel, respectively.<sup>36–38</sup>

Analogous to a specific interaction of E3 $\alpha$ /UBR1 with its cognate E2 ligase UBC2, Hect E3s bind to a distinct set of E2s, such as yeast UBC4 and UBC5 or human UbcH5, UbcH7, and UbcH8 via a specific interaction with the Hect domain.<sup>33,39–41</sup> X-ray diffraction analysis of the crystal structure of the E6-AP Hect domain bound its cognate UbcH7 reveals the overall organization of this complex as well as the detailed structural determinants responsible for the E2-E3 specificity.<sup>42</sup> Specifically, Phe-63 of the UbcH7 L1 loop was found to play a central role in determining its specificity for E6-AP. This is consistent with the fact that Phe-63 is conserved in E2s that recognize a Hect class of E3s and replacement of Phe-63 with Asn of UbcH5, another Hect class-recognizing E2, results in loss of binding to the Hect E3 RSP5.<sup>43</sup> This suggests that the L1 loop of Hect E3-recognizing E2s is the specificity loop.

**iii. Ring finger family:** Although more than 200 functionally distinct proteins in eukaryotes are found to contain the RING finger protein sequence motif and its variants, until recently no specific function(s) had been identified. The RING finger motif was initially identified in the

protein product of the human gene *RING1* and has been defined as a consensus sequence Cys-X<sub>2</sub>-Cys-X<sub>(9-39)</sub>-Cys-X<sub>(2-3)</sub>-Y(Cys/His)-X<sub>2</sub>-Cys-X<sub>(4-48)</sub>-Cys-X<sub>2</sub>-Cys where X can be any amino acid residues and Y can be either Cys as in RING-HC or His as in RING-H2.<sup>44</sup>

One of the best characterized members of the RING finger E3 ligases, c-Cbl proto-oncoprotein attenuates signaling by activated receptor protein tyrosine kinases (RPTKs) via their ubiquitination and subsequent proteasome-mediated degradation.<sup>45-47</sup> c-Cbl contains a variant SH2 domain that recognizes tyrosine phosphorylated substrates. Furthermore, it also contains a RING finger motif that recruits and activates allosterically its cognate E2s.<sup>46-48</sup> An intact RING finger motif is therefore required for ubiquitination of activated RPTKs<sup>49</sup> and its deletion or disruption aborts the function of c-Cbl.<sup>50,51</sup>

A few cognate E2s, such as UBC4, UbcH5B/C, and UbcH7, are known, and recent X-ray diffraction analysis of the c-Cbl RING and SH2 domains together with a tyrosine-phosphorylated peptide and UbcH7 provided an insight into the mechanism by which the RING finger domain recognizes its cognate E2s<sup>52</sup>: structural data support the model in which the RING finger domain serves as both a binding site that recruits the substrates and the E2s and as a scaffold that positions and orients them optimally for ubiquitin transfer. A growing number of RING finger E3 ligases have been identified and other examples of E2-RING finger E3 pairs include RAD6-RAD18 and RAD5 complex,<sup>53</sup> UBC9-PML,<sup>54</sup> and UbcH5-MDM2.<sup>55,56</sup>

**iv. Multisubunit complex family:** Multisubunit E3 ubiquitin ligase complexes, e.g., APC and SCF complexes, consist of several subunits, among which a conserved accessory protein(s) is used to select a specific substrate for ubiquitination and another component binds to its cognate E2. It is not yet established, however, whether there is a direct transfer of activated ubiquitin from bound E2 to any component of this complex prior to final covalent modification of a substrate.

The best characterized E3 ligase complex, the *anaphase-promoting complex* (APC) also known as the cyclosome, comprises 12 subunits in yeast<sup>57-59</sup> and at least 10 in mammals.<sup>60</sup> The number of known substrates are relatively small, but several of these proteins including mitotic cyclins, certain anaphase inhibitors, and spindle-associated proteins are important for mitotic progression.<sup>58</sup>

Although the function of every APC component has yet to be identified, the role of several critical subunits is understood. Basic components of APC comprise, for example, a distant cullin homolog APC2, a substrate-recognizing Cdc20, and a recently identified RING finger-containing APC11. The similarity of basic architecture of the APC and SCF complexes has recently been appreciated, suggesting a common mechanism for recognition and ubiquitination of substrates by the ubiquitin ligase complexes.<sup>61,62</sup>

In order to ubiquitinate selective cell cycle inhibitors, the APC complex associates chronologically with two different coactivator proteins, i.e., Cdc20/fizzy/Slp1 and Cdh1/Hct1/fizzy-related.<sup>63-66</sup> Cdc20 and Cdh1 both contain WD40 repeats that presumably recognize a “destruction box”, i.e., a conserved 9-amino acid residue motif found in most APC substrates. As expected, for example, deletion or disruption of a destruction box in cyclin A leads to a metaphase delay.<sup>67</sup> It should be noted that the mode of regulation of APC by the above-mentioned selective association differs in the case of Cdc20, whose expression level itself is regulated. In contrast, Cdh1/Hct1 is activated by the phosphatase Cdc14 only at specific points of cell cycle but normally phosphorylated by Cdk during most of cell cycle.<sup>59</sup>

A RING finger-containing APC11 is a recently identified APC component, which is required for ubiquitination of Clb2.<sup>68</sup> It also mediates its own ubiquitination as well as APC substrates, such as cyclin B and securin.<sup>69,70</sup> More importantly, APC11 is found to interact with APC2,

which is a cullin homolog and an essential APC component, in a similar manner as RBX1, an essential RING finger-containing SCF component, that is also homologous to APC11.<sup>71,72</sup> It is likely that APC2 and APC11 together are involved in recruiting the cognate E2, though the nature of their interactions has yet to be determined.

The SCF complex is another well-characterized E3 ligase complex that targets a number of important cell cycle regulators, such as G1 cyclins, CDK inhibitors, and other short-lived proteins.<sup>73</sup> In general, the SCF complex is composed of two evolutionary conserved factors, i.e., Skp1 and a member of the Cullin/Cdc53 family of proteins, together with an F-box protein.<sup>14,74–76</sup> Substrate-recognizing F-box proteins contain WD40 repeats or leucine-rich domains that are mainly responsible for selecting the diverse SCF substrates in a phosphorylation-dependent manner. For example, phosphorylated Sic1 is recognized by the WD40 repeats of the F-box protein Cdc4 and ubiquitinated by its cognate E2 Cdc34. Similarly, the phosphorylated form of Cln is specifically bound via the leucine-rich domain of the F-box protein Grr1. In addition to regulation by phosphorylation of substrates, F-box proteins themselves are regulated transcriptionally<sup>77,78</sup> and post-translationally.<sup>79</sup> In contrast to the WD40 repeats or leucine-rich domains, the F-box motifs of these proteins appear to be responsible for interacting with other SCF components, particularly with Skp1.

In addition to the three traditionally defined subunits of the SCF complex (Skp1, cullin/Cdc53, and *F*-box proteins), as described above, a small RING finger-containing protein Rbx1/ROC1/HRT1 is also identified as an additional essential component of the SCF complex<sup>62,71,80–82</sup>. Rbx1 interacts with different cullins and together enhances activity of the SCF complex apparently by recruiting cognate E2 Cdc34 into the SCF complex. Interestingly, Rbx1 also stimulates auto-ubiquitination of Cdc34, suggesting that Rbx1 acts as an allosteric activator of Cdc34. Interestingly, RING finger-containing Rbx1 is also an essential component of another multisubunit E3 ligase complex, VCB-CUL2 that consists of the von Hippel Lindau (VHL) tumor suppressor protein, a Skp1 homolog Elongin C, and a Cdc53 homolog Cul2. In this complex, VHL protein contains a SOCS box, a distant homolog of the *F*-box<sup>83</sup> and can be replaced with other proteins that also contain a SOCS box.

Taken all together, a core complex of cullins and RING finger proteins appears to form the basis for a multisubunit complex E3 ligase complex<sup>84,85</sup>. While this core structure binds and activates cognate E2, Skp1 in SCF and an as of yet unidentified component in APC mediates recruitment of the substrate-recognizing component, which confers substrate specificity to this complex.

## B. 20S and 26S Proteasome: Converging Points of Ubiquitinated Substrates

**1. Overall Organization of the Proteolytic System**—The structure of the 20S proteasome is well conserved in virtually all organisms ranging from archaeobacteria<sup>86</sup> to yeast<sup>87</sup> to humans<sup>88</sup>: a hollow and barrel shape consists of four stacked heptameric rings, forming a central chamber that runs through the stack from top to bottom. Each ring is composed of seven subunits, which may be classified into two groups, i.e.,  $\alpha$ -subunits that comprise the outer two rings and  $\beta$ -subunits the inner two rings. Structural and mutagenesis studies revealed that the amino terminal threonines of the  $\beta$ -subunits serve as the catalytic nucleophiles. This is in contrast to other cellular proteases, such as serine and cysteine proteases, that utilize an internal amino acid as a nucleophile.

In contrast to the ancestral proteasome found in archabacteria, the eukaryotic proteasome contains an additional 19S regulatory complex, consisting of a lid and a base<sup>89</sup> that binds to the 20S particle to form the 26S proteasome holoenzyme. While the lid recognizes ubiquitinated protein substrates with high fidelity, the base, which contains six ATPase and caps the end of the 20S proteasome core, unfolds protein substrates and threads them into the

catalytic chamber of the 20S particle, in an ATP-dependent manner.<sup>90</sup> It should be noted that the eukaryotic 20S proteasome alone shows only modest proteolytic activities that can be stimulated by treatment of SDS<sup>91–93</sup> and by association with 19S and 11S regulatory complexes.<sup>94–96</sup> As has been long expected, the 19S regulatory complex was recently shown to open a gated channel into the 20S proteasome core,<sup>97</sup> in which an access to the central chamber is blocked in the free 20S proteasome.<sup>87</sup> Similarly, the 11S regulatory complex (PA26)<sup>98</sup> was also shown to activate the 20S proteasome by opening the gate separating the sequestered proteasome internal chamber from the intracellular environment.<sup>99</sup>

Unlike typical proteases, the 20S proteasome ensures that virtually all peptide bonds within a protein substrate are susceptible to cleavage, by possessing multiple proteolytic activities in one proteolytic internal chamber. Traditionally, the proteolytic activity of the 20S proteasome is expressed by its preference to cleave a peptide bond immediately after a particular amino acid, i.e., a P1 amino acid residue of model peptides and natural polypeptide substrates.<sup>100</sup> For example, the 20S proteasome hydrolyzes a peptide bond after bulky hydrophobic amino acid residues, reminiscent of chymotrypsin. Similarly, it also cleaves a peptide bond after basic residues, analogous to trypsin, and after acidic residues.<sup>101</sup> Hence, these activities are referred to as the chymotrypsin-like (CT-L), trypsin-like (T-L), and post-glutamyl peptide hydrolyzing (PGPH) activities, respectively.<sup>102</sup> In addition to these well-characterized proteolytic activities, the 20S proteasome is also known to possess two other proteolytic activities, i.e., branched-chain amino acid-preferring (BrAAP) and small neutral amino acid-preferring (SNAAP) activities.<sup>103</sup> It awaits, however, to determine whether these activities simply reflect a broad specificity of the catalytic subunits that are responsible for the above-mentioned three classical activities<sup>104–106</sup> or a novel as of yet unidentified catalytic mechanism is responsible for BrAAP and SNAAP activities.

Attempts to map the active sites of the 20S proteasome catalytic subunits responsible for these proteolytic activities revealed that different subunits can be assigned to corresponding activities. For example, extensive mutations in the yeast proteasome provide evidence that  $\beta$ 1 (PRE3) is responsible for the PGPH activity,<sup>107,108</sup>  $\beta$ 5 (PRE2) provides for the CT-L activity, and  $\beta$ 2 (PUB1) is necessary for the T-L activity.<sup>104,109,110</sup> Based on the high sequence homology of the catalytic subunits between the yeast and mammalian proteasomes, X (mammalian counterpart to yeast  $\beta$ 5) is assigned for the CT-L activity, Y (mammalian counterpart to yeast  $\beta$ 1) for the PGPH activity, and Z (mammalian counterpart to yeast  $\beta$ 2) for the T-L activity. In general, these assignments agree with extensive inhibitor studies.<sup>111</sup>

**2. Catalytic Mechanism for the 20S Proteasome-Mediated Proteolysis**—After many years of uncertainty as to whether the 20S proteasome belongs to the classical serine or cysteine proteases, a combination of genetic, structural, and inhibitor studies have revealed the importance of the amino terminal Thr as a nucleophile catalyst in the 20S proteasome-mediated proteolysis. The first line of evidence comes from genetic studies. Mutation of the amino terminal Thr in the catalytic subunits of the 20S proteasome from *Thermoplasma acidophilum* was found to abolish the proteasome activity,<sup>112</sup> suggesting a role of this residue in the proteolysis. In contrast, other amino acid residues, such as Ser, Cys, and Asp, which potentially act as a nucleophile catalyst, did not greatly affect the proteolysis. Next, X-ray diffraction analysis showed that the proteasome inhibitor, *N*-acetyl-Leu-Leu-norleucinal (**2**) is located in proximity to the hydroxyl group of the amino terminal Thr of the catalytic subunits from *Thermoplasma* proteasome,<sup>86</sup> forming a hemiacetal intermediate between the aldehyde group of the inhibitor and the hydroxyl group of the amino terminal Thr, reminiscent of the tetrahedral intermediate of a protease reaction. Later, it was reported that all of the six catalytic  $\beta$ -subunits in the yeast proteasome covalently bind to the same inhibitor *N*-acetyl-Leu-Leu-norleucinal in an analogous manner.<sup>87</sup> Finally, mechanistic insight into the role of the amino terminal Thr in the proteasome proteolysis has come from several inhibitor studies. Mode-of-

action studies revealed that natural product proteasome inhibitor lactacystin (**15**) targets the 20S proteasome and inhibits irreversibly the CT-L and T-L activities of the 20S proteasome, by covalent modification of the amino terminal Thr of the catalytic  $\beta$ -subunit.<sup>113</sup> Recently, another natural product proteasome inhibitor epoxomicin (**17**) was also found to target the 20S proteasome,<sup>114,115</sup> with concomitant modification of the amino terminal catalytic Thr of the 20S proteasome by its  $\alpha',\beta'$ -epoxyketone pharmacophore.<sup>116</sup>

From these lines of evidence, the 20S proteasome is classified as an amino terminal nucleophile (Ntn) hydrolase that contains the amino terminal Thr acting as the nucleophile catalyst. Other examples of such Ntn hydrolases include penicillin acylase with an amino terminal Ser, glutamine PRPP amidotransferase with an amino terminal Cys,<sup>117,118</sup> and aspartylglucosaminidase with the amino terminal Thr.<sup>119</sup> All Ntn hydrolases share a common Ntn hydrolase fold.

Considering the general mechanisms for the proteolysis by other Ntn hydrolases and genetic, structural, and inhibitor studies of the 20S proteasome, the following mechanism was proposed for the proteolysis catalyzed by the 20S proteasome (Fig. 1). In step 1, as the hydroxyl group of the amino terminal Thr-1 attacks the peptide carbonyl group of the scissile bond, a proton is transferred from the hydroxyl group of the nucleophile to the uncharged  $\alpha$ -amine group of the same Thr-1, most likely through an intermediate water molecule. Evidence of the involvement of a water molecule comes from its proximity to the amino terminal Thr-1 in the active site of the catalytic subunit, as observed in the crystal structure of both penicillin acylase and the 20S proteasome.<sup>87,118</sup> It should be noted that potential involvement of Glu-17 or Lys-33 as a general acid-base catalyst is also suggested.<sup>120</sup> The tetrahedral addition intermediate then breaks down to result in the formation of the covalent acyl enzyme intermediate, with a proton transfer to the leaving group (step 2). Hydrolysis of the acyl enzyme intermediate is proposed to occur by a similar mechanism as described above for its formation. The free  $\alpha$ -amine group of the amino terminal Thr-1 removes a proton from the attacking water molecule again through an intermediate water molecule (step 3). A proton is finally transferred to the oxygen atom of Thr-1 as the product is expelled from the tetrahedral addition intermediate (step 4).

Just as chymotrypsin, trypsin, and elastase are synthesized as inactive proenzymes, e.g., chymotrypsinogen and trypsinogen, the catalytic  $\beta$ -subunits of the 20S proteasome are synthesized in an inactive form containing an amino terminal prosequence that is removed upon assembly into the 20S proteasome core. This prevents inadvertent proteolysis of cellular proteins by the newly synthesized  $\beta$ -subunits of the 20S proteasome.<sup>121,122</sup> The  $\beta$ -subunits of the 20S proteasome from *Thermoplasma* contain 8 amino acid-long prosequences and all 14 subunits are processed and become catalytically active. In eukaryotes, however, prosequences are longer and more heterogeneous<sup>123,124</sup> and only three subunits (PRE2, PRE3, and PUB1) of the seven distinct  $\beta$ -subunits of the yeast proteasome are processed and become catalytically active.<sup>107–109,125</sup> Similarly, X, Y, and Z  $\beta$ -subunits of mammalian proteasome are catalytically active. The processing event appears to be autocatalytic as in other Ntn hydrolases<sup>117</sup> and coupled to proteasome assembly.

### 3. REPRESENTATIVE CELLULAR SUBSTRATES AND PROCESSES TARGETED BY THE UBIQUITIN-PROTEASOME PATHWAY

Orderly progression through the cell cycle requires programmed and periodic expression of cell cycle proteins. Cyclins were first identified as proteins whose levels oscillate during the cell cycle.<sup>126,127</sup> This oscillation of cyclins was later found to be due to the regulated degradation mediated by the ubiquitin-proteasome pathway<sup>128</sup> and the proteasome-mediated proteolysis has now emerged as a major regulatory mechanism of the cell division cycle.



Among many, mammalian cyclins A, B, D, and E, CDK inhibitor p27, p21, transcription factor E2F, Rb, the tumor suppressor p53 proteins<sup>73,129</sup> and yeast Clns, Clbs, Sic1, and Far1<sup>130</sup> are best characterized. Given the fact that the inhibition of the ubiquitin-proteasome pathway results in blockage of cell cycle progression at many different phases, this antiproliferative activity of the proteasome inhibitors has been suggested to be used against various forms of tumors.

The transcription factor p53 plays a role of the key integrator in an intricate network of proteins of diverse functions that sense a variety of stress signals.<sup>131</sup> The activation of p53 in response to such signals results in apoptosis or cell-cycle arrest, thereby maintaining the integrity of healthy cells and thus preventing the transformation to tumor cells. Not surprisingly, the tumor repressor p53 has been found as one of the most frequently mutated genes in many types of cancers. Its levels are normally quite low mainly due to its very rapid turnover and the ubiquitin-proteasome pathway is responsible for regulating its level.<sup>132,133</sup> Proteasome inhibitors indeed can inhibit its degradation, resulting in accumulation of p53-ubiquitin aggregates. One of the major regulators of p53 is MDM2,<sup>134,135</sup> which is inducible by its cellular substrate p53. MDM2 binds to the amino terminal trans-activation domain of p53, thereby resulting in inhibition of p53 transcriptional activity. Moreover, MDM2 binding to p53 also allows ubiquitination of both p53 and itself, eventually leading to destruction by the proteasome-mediated proteolysis.<sup>134,136</sup>

MDM2 transfers activated ubiquitin to both p53 and itself with the help of its cognate E2, UbcH5.<sup>55,56</sup> Recognition of p53 is mainly mediated by binding of MDM2 via its carboxy terminal RING finger domain to the trans-activation domain of p53.<sup>136,137</sup> It should be noted that phosphorylation of Ser in the amino terminus of p53 stabilizes p53 as a result of decreased binding to MDM2.<sup>138-141</sup> Conversely, phosphorylation of MDM2 also plays a role in regulating p53 stability.<sup>142,143</sup>

The transcriptional factor NF- $\kappa$ B (*nuclear factor  $\kappa$ B*) is another regulatory protein, whose mode of activation is controlled by the ubiquitin-proteasome pathway. Originally thought to be a B cell-specific transcription factor,<sup>144</sup> NF- $\kappa$ B is an ubiquitous and central player in a variety of cellular processes, including immune and inflammatory responses, apoptosis, and cellular proliferation.<sup>145-150</sup> Different forms of NF- $\kappa$ B exist, each composed of various members of the Rel family, reflecting the complexity of its response to diverse stimuli. In resting cells without extracellular stimuli, NF- $\kappa$ B is held latent in the cytoplasm as a complex bound with unphosphorylated I $\kappa$ B, thereby blocking the nuclear translocation of NF- $\kappa$ B. In response to the proinflammatory cytokines, such as tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) and interleukin-1 (IL-1), for example, a series of signal transduction cascades are initiated, eventually leading to activation of a multisubunit I $\kappa$ B kinase (IKK). Activated IKK in turn phosphorylates the critical Ser residues in the regulatory domain of a member of the inhibitor  $\kappa$ B (I $\kappa$ B) family. Phosphorylation of I $\kappa$ B by IKK, however, leads to degradation of I $\kappa$ B. As a result, free NF- $\kappa$ B is allowed to translocate into the nucleus and activates transcription of  $\kappa$ B sequence-specific genes.

Extensive study of such signal-induced destruction of I $\kappa$ B $\alpha$  (the best characterized member of the I $\kappa$ B family) has revealed that the ubiquitin-proteasome pathway plays a crucial role in NF- $\kappa$ B activation. Specifically, it is found that a variety of inducing signals converges on IKK  $\alpha$  and  $\beta$ , which eventually phosphorylate highly conserved Ser-32 and -36 of I $\kappa$ B $\alpha$ .<sup>151,152</sup> These two highly conserved Ser residues reside in the amino terminal regulatory domain that precedes a well-conserved ankyrin core and a PEST domain.<sup>147,149</sup> Upon phosphorylation, I $\kappa$ B $\alpha$  is recognized by the SCF complex containing the F-box protein  $\beta$ -TrCP<sup>153-155</sup> and the RING finger protein ROC1.<sup>81</sup> The resulting E2-E3 complex in turn covalently attaches polyubiquitination chain to I $\kappa$ B $\alpha$  that is eventually targeted for degradation by the 26S

proteasome.<sup>156–158</sup> It should be noted that other members of IκBs, such as Cactus in *Drosophila* and IκBβ and ε in mammals, also share a similar amino terminal regulatory domain that contains two invariant Ser residues within a defined consensus sequence and are believed to undergo a similar signal-induced degradation mediated by the ubiquitin-proteasome pathway.

Interestingly, the ubiquitin-proteasome pathway is also implicated in controlling the activity of NF-κB pathway through a limited proteolysis of p105.<sup>156,159–162</sup> Full length p105 forms a stable complex with p65,<sup>163–165</sup> in a similar manner as a ternary complex formation of p50/p65 dimer bound with IκB. Analogous to recognition of IκBα, the SCF complex containing the F-box protein β-TrCP recognizes p105, albeit two different recognition motifs are used for IκBα and p105.<sup>166</sup> While an exact mechanism for p105 processing in response to NF-κB inducing stimuli is yet to be determined, results are beginning to shed light on the importance of IKK-mediated phosphorylation of p105 that leads to accelerated processing of p105.<sup>166, 167</sup> In contrast, pathways involving cotranslational degradation by the 26S proteasome of newly synthesized p105 appear to provide an alternative mechanism to control the activity of NF-κB via a balanced production of p50 and p105 in the cells.<sup>168,169</sup>

The importance of the ubiquitin-proteasome machinery in regulating critical biological processes culminates as this system is shown to be used to generate antigenic peptides from cytosolic proteins for presentation on MHC class I molecules.<sup>170,171</sup> As to the definitive role of ubiquitination reaction for the generation of the antigenic peptides, conflicting results are reported.<sup>172–174</sup> In contrast, as to the role of the proteolysis mediated by the 26S proteasome, ingenious use of proteasome aldehyde inhibitors clearly demonstrated that effective presentation of the antigenic peptides is inhibited in proteasome inhibitor-treated cells,<sup>175, 176</sup> because of the accumulation of MHC class I molecules continuously bound with TAP in the ER due to the lack of proper antigenic peptides.<sup>177</sup> Later, the more specific proteasome inhibitor lactacystin (**15**) was also found to reduce antigen presentation in a similar manner.<sup>178,179</sup> Interestingly, after stimulation of antigen-presenting cells with interferon-γ (INF-γ), three constitutive β-subunits, X, Y, and Z, are exchanged by LMP7, LMP2, and MECL1, respectively. These new subunits possess different profiles for proteolytic activities, most likely allowing a more efficient generation of antigenic peptides recognized by the MHC class I molecules. Moreover, INF-γ also induces proteasome activator PA28, which is thought to play an important role in MHC class I antigen presentation. Exact nature of roles of such INF-γ-inducible subunits and activators is currently under intense scrutiny.

It is well known that viruses exploit host cells' machinery for their own replication. The ubiquitin-proteasome pathway is one of these intracellular processes co-opted by viruses. For example, the ubiquitin-proteasome pathway has been implicated in retrovirus assembly through the finding that an unusually high concentration of free ubiquitin is present in avian leukosis virus (ALV).<sup>180</sup> Recently human immunodeficiency virus type 1 (HIV-1), simian immunodeficiency virus (SIV), and Moloney murine leukemia virus (Mo-MuLV)<sup>181</sup> have also been shown to contain high level of free ubiquitin inside of mature virus. Moreover, it was found that about 30% of the mature HIV-1 and Mo-MuLV Gag proteins are ubiquitinated<sup>181</sup> and up to 50% of Gag proteins are conjugated with ubiquitins in the released virus-like particles (VLPs).<sup>182</sup> Although it is yet to decipher a detailed mechanism, the ubiquitin-proteasome pathway was recently found to be an important player in retrovirus assembly.<sup>182–184</sup>

The involvement of the ubiquitin-proteasome pathway in retrovirus assembly, therefore, provides an excellent opportunity to develop a new line of anti-HIV therapeutic strategies. Of particular note, it was found that retrovirus budding or proteolytic maturation is inhibited upon treatment of infected cells with proteasome-specific inhibitors, e.g., lactacystin (**15**) or

epoxomicin (**17**) at concentrations well below their cytotoxicity levels.<sup>183,184</sup> This should provide a starting point in the development of potential anti-HIV drugs.

Human cytomegalovirus (CMV) represents yet another example how viruses exploit the ubiquitin-proteasome machinery to persist infection. Among a number of genes that CMV carries to inhibit the surface expression of MHC class I molecules, US2 and US11 encode ER-resident proteins, which bind to newly synthesized MHC class I molecules in the ER and target them to degradation by the ubiquitin-proteasome pathway.<sup>185,186</sup> As a result, the presentation of antigenic viral proteins is inhibited, allowing viruses to elude the immune surveillance.

#### 4. HUMAN DISEASES DUE TO THE DEFECTS OF THE UBIQUITIN-PROTEASOME PATHWAY

Reflecting the fact that the regulation of diverse short-lived proteins and regulatory proteins is mediated by the ubiquitin-proteasome pathway, it is not surprising that defects of various components of this complex biochemical machinery result in a range of human diseases. As a result, these components would provide an attractive novel target for therapeutic intervention. A few examples of inherited and acquired human diseases due to the defects of the ubiquitin-proteasome pathway are described below, emphasizing the molecular mechanism of pathogenesis.

##### A. Inherited Disorders

**1. Angelman's Syndrome**—Angelman's syndrome is a complex neurological disorder<sup>187</sup> due to various genetic mechanisms that map to human chromosome 15q11–q13.<sup>188</sup> Clinical characteristics of this disorder include developmental delay, speech impairment, movement or balance disorder, and behavioral uniqueness.<sup>189</sup> Further genetic analysis revealed that truncated mutants of the UBE3A gene on chromosome 15q were identified in some patients with Angelman's syndrome.<sup>190,191</sup> UBE3A gene encodes a protein called E6-AP protein ligase (also known as ubiquitin-protein ligase or E3). Although the true substrate(s) of this E6-AP in AS patients has not yet been identified, the ubiquitin-proteasome pathway plays an important role during brain development and perturbation of this pathway causes a neuropathological disorder.

**2. Liddle Syndrome**—Liddle et al.<sup>192</sup> recognized this rare hereditary disorder in a family who were unable to maintain the proper balance of salt and water in the body, resulting in abnormally high blood pressure. The molecular mechanism of Liddle syndrome was later understood by Yale researchers<sup>193</sup> who observed mutations in the carboxy terminus of  $\beta$  and  $\gamma$  subunit of the epithelial sodium channel in the kidney. Among many different mutations, deletion or mutation of the proline-rich (PPxY) region leads to constitutive activation of the kidney sodium channel, resulting in retention of excessive amounts of salt and water. Using a yeast two-hybrid screen and in vitro binding studies,<sup>37</sup> WW domain of an ubiquitin ligase, Nedd4, is found to bind specifically to the PPxY sequences of the above-mentioned kidney sodium channel. Taken together, these findings suggest a novel mechanism regulating sodium reabsorption, in which failure of proper ubiquitination of the sodium channel results in increased retention of the sodium channel at the cell surface and thus excessive reabsorption of sodium and water leading to hypertension. It should be noted, however, that this short-lived sodium channel, after ubiquitination, is targeted and degraded in the lysosome, but not by the 26S proteasome machinery.

##### B. Acquired Disorders

**1. Cervical Cancer**—The most important risk factor for cervical cancer is human papillomavirus (HPV) infection. In cases of cervical cancer caused by the high-risk strains of

HPV, levels of the tumor suppressor protein p53 were found to be unusually low due to the presence of the E6 proteins encoded by the oncogenic HPV.<sup>194</sup> This E6-promoted degradation of p53 involves the ubiquitin-proteasome pathway and represents a major mechanism, by which virus transforms the host cells. The E6 oncoprotein was later found to modify the functions of E6-AP<sup>31,195</sup> whose absence prevents ubiquitination of p53 by E6-AP.<sup>196</sup> Specifically, E6 appears to function as an adapter protein to maintain a ternary complex of E6-AP ubiquitin-protein ligase (E3), its cognate UbcH8 ubiquitin-conjugating enzyme (E2), and a target substrate to ensure specific ubiquitination of substrate molecules.<sup>41,197</sup> Interestingly, E6 also promotes the ubiquitination and degradation of E6-AP.<sup>198</sup>

**2. Colorectal Cancer**—Colorectal cancer, which arises in the epithelium of the lumen of the colon and rectum, is the second most common cause of cancer death in the United States. Generally speaking, the transformation of the normal epithelial cells into cancer cells occurs through a multistage process as a result of many different defects. One of most well-characterized genetic defects is found in the APC (adenomatous polyposis coli) gene located on chromosome 5q21. Mutations of the APC gene have been documented in familial adenomatous polyposis and in more than 80% of the sporadic colorectal cancer patients.<sup>199</sup>

Among its many functions, APC is known to control the cellular level of  $\beta$ -catenin by forming a complex with Axin, which recruits and facilitates ubiquitination of  $\beta$ -catenin for subsequent degradation by the 26S proteasome.<sup>200,201</sup> This process appears to be dependent on the phosphorylation of both APC and  $\beta$ -catenin by glycogen synthase kinase-3 (GSK-3).<sup>202</sup> In cancer cells expressing mutant APC,  $\beta$ -catenin accumulates,<sup>203,204</sup> and interacts with T-cell factor as well as activates transcription of the proto-oncogenes, such as cyclin D1 and c-myc.<sup>205–207</sup> Mutations of Ser to amino acid residues that cannot be phosphorylated stabilize  $\beta$ -catenin.<sup>208</sup> It appears that ubiquitination of  $\beta$ -catenin is catalyzed by the SCF complex and its cognate E2. A receptor component of the SCF E3 ligase complex, i.e., F box- and WD domain-containing  $\beta$ -TrCP binds to the phosphorylated form of  $\beta$ -catenin, and over-production of a defective  $\beta$ -TrCP blocks  $\beta$ -catenin degradation.<sup>155,209,210</sup>

**3. Alzheimer's Disease**—Alzheimer's disease is a chronic brain disorder due to a progressive degeneration of brain tissue, leading to loss of mental functions, such as memory and learning. Alzheimer's disease is marked by abnormal aggregates (senile plaques) and irregular knots (neurofibrillary tangles) of brain matter. By immunohistochemical analysis of protein contents in intracellular inclusion bodies, ubiquitin is found in both neurofibrillary tangles and senile plaques.<sup>211,212</sup> Although it is not yet clear whether accumulation of ubiquitin conjugates is primary or secondary, a growing number of evidence indicate the involvement of the ubiquitin-proteasome pathway in Alzheimer's disease. For example, findings of a simultaneous frameshift mutation of both  $\beta$  amyloid precursor protein ( $\beta$ APP) and ubiquitin have implicated the ubiquitin-dependent pathway in the pathogenesis of Alzheimer's disease.<sup>213</sup> In addition, treatment of cells expressing presenilins 1 and 2 (PS1 and PS2) with proteasome inhibitors was shown to increase the PS1/PS2-mediated production of both APP $\alpha$  and A $\beta$ 40, which are  $\beta$ APP maturation products.<sup>214</sup> Senile plaques are thought to derive from the abnormal level of A $\beta$ 40 production.<sup>215</sup> PS1 and PS2 are also found to be the proteasome substrates.<sup>216–218</sup> Taken altogether, the ubiquitin-proteasome pathway appears to control the level of PS1 and PS2, thereby regulating the  $\beta$ APP maturation pathway.

## 5. PROTEASOME INHIBITORS

Most currently available inhibitors of the ubiquitin-proteasome pathway directly target and inhibit the 20S proteasome, the core of the proteolysis machinery, rather than the upstream ubiquitination and recognition of ubiquitinated protein substrates. These proteasome inhibitors are broadly categorized into two groups: synthetic analogs and natural products. Synthetic

inhibitors are peptide-based compounds with diverse pharmacophores. These include peptide benzamides, peptide  $\alpha$ -ketoamides, peptide aldehydes, peptide  $\alpha$ -ketoaldehydes, peptide vinyl sulfones, and peptide boronic acids. In contrast, natural product proteasome inhibitors display a variety of scaffolds of core structures and pharmacophores. Known natural product proteasome inhibitors include linear peptide epoxyketones, peptide macrocycles,  $\gamma$ -lactam thiol ester, and epipolythio-dioxopiperazine toxin. The inhibitory mechanisms and the limits and potentials of proteasome inhibitors are discussed in the following.

### A. Synthetic Proteasome Inhibitors

Peptide aldehydes have long been used as inhibitors for both serine and cysteine proteases. Given that the aldehyde functional group is readily subject to a nucleophilic attack by hydroxyl or thiol groups and that the proteasome uses the hydroxyl group of the amino terminal threonine as a nucleophile, it is not surprising that the commercially available peptide aldehydes were the first proteasome inhibitor family identified (Fig. 2). In the early 1980s, leupeptin (**1**), a standard serine (trypsin, plasmin) and cysteine (papain, cathepsin B) protease inhibitor, was already recognized as a T-L activity blocking agent of the 20S proteasome.<sup>101</sup> Later, calpain inhibitors I (**2**) and II (**3**) were also shown to inhibit the CT-L activity of the 20S proteasome.<sup>219,220</sup> Upon binding to the active site of the 20S proteasome, a peptide aldehyde forms a covalent hemiacetal adduct that is reversible under physiological conditions (Fig. 3). Since peptide aldehydes can be easily prepared and optimized, researchers have developed myriad of aldehyde inhibitors with higher potency as well as increased selectivity toward the CT-L activity of the 20S proteasome (Fig. 2). Such examples include MG115 (**4**), MG132 (**5**)<sup>175</sup> and PSI (**6**),<sup>221</sup> which are all potent and CT-L selective inhibitors that are widely used in studying the role of the proteasome in various cellular processes. Similarly, other peptide aldehyde inhibitors have been synthesized to study other proteasomal activities, such as BrAAP activity.<sup>222</sup> Meanwhile, researchers have also attempted to improve peptide aldehydes' potency by adding an additional ketone moiety at  $\alpha$  position, yielding a glyoxal (**7**).<sup>223</sup>

Although these peptide aldehydes, in general, are cell-permeable, potent inhibitors of the 20S proteasome, and are still widely used in biological studies, the lack of specificity due in part to the presence of highly reactive aldehyde functional group is a major limitation for their use as potential therapeutic agents or as molecular probes in dissecting complex signaling pathways. To overcome such limitations, researchers have attempted to develop non-reactive peptide inhibitors (Fig. 4), such as  $\alpha$ -ketocarbonyl and boronic ester derivatives,<sup>224</sup> indanone dipeptide benzamides,<sup>225</sup> and P'- extended  $\alpha$ -ketoamides.<sup>226</sup> Non-aldehyde irreversible proteasome inhibitors have also been developed (Fig. 5), such as tripeptides  $\alpha'$ , $\beta'$ - epoxyketones<sup>227</sup> and vinyl sulfones.<sup>228</sup>

Vinyl sulfones were first introduced as cysteine protease inhibitors.<sup>229,230</sup> Although vinyl sulfones are sufficiently inert in the absence of a target, it is well characterized that they are capable of forming a hydrogen bond in the active site of enzymes, thereby becoming more electrophilic (Fig. 5). Despite being more widely known as inhibitors of cysteine proteases, peptide vinyl sulfones have also been developed as potent inhibitors toward the 20S proteasome and successfully employed for many biological studies.<sup>228,231</sup> Peptide vinyl sulfones have also been shown to be irreversible and active site-directed proteasome inhibitors by modification of the hydroxyl group of the amino terminal threonine (Fig. 5).<sup>185,228,232,233</sup> Nevertheless, the lack of specificity is a major concern for this class of inhibitors, since the peptide vinyl sulfones inhibit both the 20S proteasome and other cysteine proteases.<sup>229,232</sup>

Another class of peptide-based inhibitors exploits the boronic acid functional group.<sup>234</sup> It should be noted that this class of inhibitors is thought to exhibit proteasome inhibition via a non-covalent complex formation. Considering no difference in the potency of the boronic ester

derivatives as compared to that of the corresponding aldehyde derivatives,<sup>224</sup> the inhibitory potency and the target selectivity towards the 20S proteasome of boronic acid-based inhibitors are quite remarkable. This is presumably due to the fact that an empty *p*-orbital on a boron atom is positioned to accept the oxygen lone pair of the amino terminal threonine residue of the 20S proteasome to form a stable tetrahedral intermediate (Fig. 6). The stable tetrahedral borane complex allows the peptide chain length of the boronic acid-based inhibitor to be truncated to a dipeptide with good retention of inhibitory activity. This provides practical advantages, such as solubility and membrane permeability, as a potential therapeutic agent. It should be noted that, for other class of proteasome inhibitors, at least three amino acid chains are required to moderately inhibit the proteasomal activity.<sup>223,228,235</sup>

The most well characterized compound of this class is a dipeptide boronic acid PS-341 (**14**).<sup>234,236</sup> Analogous to many other proteasome inhibitors that block cell cycle progression, PS-341 treatment also results in accumulation of cells in the G<sub>2</sub>-M phase,<sup>237</sup> eventually leading to apoptosis after prolonged treatments of cells.<sup>238–240</sup> Moreover, PS-341 inhibits the proteasome mediated-IκBα degradation and NFκB-dependent gene expression in vivo<sup>236</sup> and reduces tumor growth in both murine and human xenograft models.<sup>237,241</sup> To exploit such effects, PS-341 is currently under clinical evaluation for advanced breast and prostate cancer.<sup>242</sup>

## B. Natural Product Proteasome Inhibitors

While the synthetic inhibitors mentioned above have been rationally designed, synthesized, and optimized, nature has also provided selective and potent proteasome inhibitors. For example, lactacystin (**15**) is a *Streptomyces lactacystinaeus* metabolite that was discovered on the basis of its ability to induce neurite outgrowth in the murine neuroblastoma cell line Neuro-2a.<sup>243,244</sup> Subsequently, others showed that lactacystin also inhibited cell cycle progression.<sup>245,246</sup> Later, Schreiber et al.<sup>113</sup> showed that lactacystin targets the 20S proteasome by an irreversible modification of the amino terminal threonine of β-subunits. It should be noted that the active component of lactacystin is the *clasto*-lactacystin β-lactone (**16**)<sup>247</sup> that is a rearrangement product of lactacystin in aqueous condition and reacts with the hydroxyl group of the amino terminal threonine to make an ester adduct (Fig. 7). Despite initial reports of high proteasome specificity and its wide use in biological studies, there have been reports that lactacystin also inhibits other cellular proteases.<sup>248–250</sup> Moreover, while many elegant synthetic strategies have been achieved over the years,<sup>251</sup> its complex synthesis has hampered the development of lactacystin-based therapeutic agents.

Meanwhile, in an effort to search for antitumor agents displaying specific activity against B16 murine melanoma, Hanada et al.<sup>252</sup> found epoxomicin (**17**) from an unidentified actinomycete strain No. Q996-17. Epoxomicin (**17**) is a member of growing family of linear peptide α',β'-epoxyketone natural products (Fig. 8). Recently, it has been shown that epoxomicin specifically targets the 20S proteasome.<sup>114,115</sup> Unlike other classes of proteasome inhibitors that show non-target specificity, epoxomicin (**17**) is highly specific for the 20S proteasome. As revealed by the crystal structure of the yeast 20S proteasome complexed with epoxomicin, this unique specificity of epoxomicin is a result of a six-membered morpholino ring formation between the amino terminal catalytic Thr-1 of the 20S proteasome and the α',β'-epoxyketone pharmacophore of epoxomicin (Fig. 9).<sup>116</sup> In addition, eponemycin (**18**), an anti-angiogenic linear peptide α',β'-epoxyketone isolated from *Streptomyces Hygroscopicus* No. P247–271 on the basis of its specific activity against B16 melanoma,<sup>253</sup> has been shown to target the 20S proteasome as well.<sup>254</sup> More recently, other linear peptide α',β'-epoxyketone natural products have been isolated directly on the basis of proteasome inhibition screening from microbial metabolites (Fig. 8). Examples include TMC-86A (**19**) and B (**20**) from *Streptomyces* sp. TC 1084,<sup>255</sup> TMC-89A and B (**21**) from *Streptomyces* sp. TC 1087<sup>256</sup> and TMC-96 (**22**) from

*Saccharothrix* sp. TC 1094.<sup>255</sup> The facile syntheses of linear peptide  $\alpha',\beta'$ -epoxyketones has prompted the development of more potent peptide  $\alpha',\beta'$ -epoxyketones, such as YU101 (**23**) that was developed by the optimization of the amino acids of the P2–P4 positions to maximize its potency toward the CT-L activity.<sup>235</sup>

While lactacystin and epoxomicin are the best known natural product inhibitors of the 20S proteasome, there have been other potent natural product proteasome inhibitors with novel structures. For example, in the course of proteasome inhibitor screening procedure, Kohno et al.<sup>257</sup> found a series of TMC-95 (**24**) from the fermentation broth of *Apiospora montagnei* Sacc. TC 1093 (Fig. 10). Despite their unusual macrocyclic peptide architecture, they possess potent inhibitory activity toward the CT-L activity of the 20S proteasome.<sup>258</sup> Given that most well known potent proteasome inhibitors are the linear peptide backbone-based compounds, it will be interesting to see how the active site of the 20S proteasome can accommodate the macrocyclic ring of TMC-95s. Another unexpected class of natural product proteasome inhibitors includes gliotoxin (**25**), a member of the fungal epipolythiodioxopiperazine toxins that are characterized by a heterobicyclic core containing a disulfide bridge(s) (Fig. 10). Gliotoxin was originally identified as a potent inhibitor of NF- $\kappa$ B activation in T and B cells.<sup>259</sup> Recently, Kröll et al.<sup>260</sup> showed that gliotoxin noncompetitively targets the CT-L activity of the 20S proteasome and that the disulfide bridge is responsible for its inhibitory action.

Although biochemical basis of catalytic activity generated by each subunit has been extensively analyzed by classical genetic mutation and X-ray crystal structure of the 20S proteasome, it is not yet clear how each catalytic activity contributes to the overall biological processes. To further separate the role(s) of the proteasome catalytic subunits, inhibition of each proteolytic activity is required. Most most of the synthetic and natural proteasome inhibitors described above are, however, CT-L activity-directed compounds. Moreover, only a limited number of compounds have been shown to inhibit the PGPH or T-L activities of the 20S proteasome. Therefore, a new generation of compounds that specifically inhibit the PGPH or T-L activities may be required to perform a careful analysis of proteasome subunit function and to gain insights into the possibility for potential therapeutic intervention. For example, Loidl et al.<sup>261</sup> developed a T-L activity specific aldehyde inhibitor (**27**) by structure-based rational design and a bivalent T-L specific proteasome inhibitor (**28**), in which two tripeptide aldehydes were linked through a polymeric spacer that is appropriate for simultaneous binding at two active sites.<sup>262</sup> Another interesting but not fully understood proteasome inhibitor 4-hydroxy-2-nonenal (HNE) (**29**) is a major end product of lipid peroxidation (Fig. 11) and is associated with the decrease of both the T-L and the PGPH but not the CT-L activities during in vivo oxidative stress.<sup>263</sup> Further investigation of HNE's mode(s) of action may prove to be useful for the design of non-peptidic PGPH or T-L specific inhibitors.

To probe the role of different catalytic subunits in in vivo and in vitro proteasomal degradation, we have recently developed a series of PGPH-specific peptide  $\alpha',\beta'$ -epoxyketones by optimizing the amino acids at the P1-P4 positions.<sup>264</sup> Successful application of these compounds including YU102 (**30**) in cell-based protein degradation assays in living cells revealed that selective PGPH inhibition was not sufficient to inhibit protein degradation, indicating that the CT-L and PGPH sites function independently.

## 6. CONCLUSION

Given that the ubiquitin-proteasome pathway is involved in so many critical cellular processes, proteasome inhibitors are of great interest as potential therapeutics. Indeed, a boronate inhibitor and a lactacystin inhibitor are currently in clinical trials for cancer and for stroke-associated ischemia reperfusion injury, respectively. In order to improve the safety of proteasome-inhibitor drugs and enable more specific inhibition of biological processes, however, attempts

to target earlier steps of ubiquitin-proteasome pathway are desirable. Although such inhibitors are not yet available, the growing amount of information about cellular substrates and components of ubiquitin conjugation cascade may aid the design of potential E2 or E3 inhibitors.

## REFERENCES

1. Vijay-Kumar S, Bugg CE, Wilkinson KD, Vierstra RD, Hatfield PM, Cook WJ. *J Biol Chem* 1987;262:6396–6399. [PubMed: 3032965]
2. Vijay-Kumar S, Bugg CE, Wilkinson KD, Cook WJ. *Proc Natl Acad Sci USA* 1985;82:3582–3585. [PubMed: 2987935]
3. Vijay-Kumar S, Bugg CE, Cook WJ. *J Mol Biol* 1987;194:531–544. [PubMed: 3041007]
4. Weber PL, Brown SC, Mueller L. *Biochemistry* 1987;26:7282–7290. [PubMed: 2827749]
5. McGrath JP, Jentsch S, Varshavsky A. *Embo J* 1991;10:227–236. [PubMed: 1989885]
6. Hatfield PM, Vierstra RD. *J Biol Chem* 1992;267:14799–14803. [PubMed: 1634524]
7. Jentsch S. *Annu Rev Genet* 1992;26:179–207. [PubMed: 1336336]
8. Hochstrasser M. *Annu Rev Genet* 1996;30:405–439. [PubMed: 8982460]
9. Sung P, Prakash S, Prakash L. *J Mol Biol* 1991;221:745–749. [PubMed: 1658333]
10. Sommer T, Jentsch S. *Nature* 1993;365:176–179. [PubMed: 8396728]
11. Goebel MG, Yochem J, Jentsch S, McGrath JP, Varshavsky A, Byers B. *Science* 1988;241:1331–1335. [PubMed: 2842867]
12. Seufert W, Futcher B, Jentsch S. *Nature* 1995;373:78–81. [PubMed: 7800043]
13. Willems AR, Lanker S, Patton EE, Craig KL, Nason TF, Mathias N, Kobayashi R, Wittenberg C, Tyers M. *Cell* 1996;86:453–463. [PubMed: 8756727]
14. Bai C, Sen P, Hofmann K, Ma L, Goebel M, Harper JW, Elledge SJ. *Cell* 1996;86:263–274. [PubMed: 8706131]
15. Dohmen RJ, Madura K, Bartel B, Varshavsky A. *Proc Natl Acad Sci USA* 1991;88:7351–7355. [PubMed: 1651502]
16. Ciechanover A. *Cell* 1994;79:13–21. [PubMed: 7923371]
17. Hershko A, Ciechanover A. *Annu Rev Biochem* 1998;67:425–479. [PubMed: 9759494]
18. Ponzio G, Rossi B, Lazdunski M. *J Biol Chem* 1983;258:8201–8205. [PubMed: 6305977]
19. Bartel B, Wunning I, Varshavsky A. *Embo J* 1990;9:3179–3189. [PubMed: 2209542]
20. Sung P, Berleth E, Pickart C, Prakash S, Prakash L. *Embo J* 1991;10:2187–2193. [PubMed: 2065660]
21. Madura K, Dohmen RJ, Varshavsky A. *J Biol Chem* 1993;268:12046–12054. [PubMed: 8505328]
22. Watkins JF, Sung P, Prakash S, Prakash L. *Genes Dev* 1993;7:250–261. [PubMed: 8436296]
23. Reiss Y, Kaim D, Hershko A. *J Biol Chem* 1988;263:2693–2698. [PubMed: 3343227]
24. Gonda DK, Bachmair A, Wunning I, Tobias JW, Lane WS, Varshavsky A. *J Biol Chem* 1989;264:16700–16712. [PubMed: 2506181]
25. Madura K, Varshavsky A. *Science* 1994;265:1454–1458. [PubMed: 8073290]
26. Byrd C, Turner GC, Varshavsky A. *Embo J* 1998;17:269–277. [PubMed: 9427760]
27. Turner GC, Du F, Varshavsky A. *Nature* 2000;405:579–583. [PubMed: 10850718]
28. Xie Y, Varshavsky A. *Embo J* 1999;18:6832–6844. [PubMed: 10581257]
29. Huibregtse JM, Scheffner M, Beaudenon S, Howley PM. *Proc Natl Acad Sci U S A* 1995;92:2563–2567. [PubMed: 7708685]
30. Huibregtse JM, Scheffner M, Howley PM. *Embo J* 1991;10:4129–4135. [PubMed: 1661671]
31. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. *Cell* 1993;75:495–505. [PubMed: 8221889]
32. Oda H, Kumar S, Howley PM. *Proc Natl Acad Sci USA* 1999;96:9557–9562. [PubMed: 10449731]
33. Schwarz SE, Rosa JL, Scheffner M. *J Biol Chem* 1998;273:12148–12154. [PubMed: 9575161]
34. Scheffner M, Nuber U, Huibregtse JM. *Nature* 1995;373:81–83. [PubMed: 7800044]
35. Huibregtse JM, Yang JC, Beaudenon SL. *Proc Natl Acad Sci USA* 1997;94:3656–3661. [PubMed: 9108033]



36. Varshavsky A. *Genes Cells* 1997;2:13–28. [PubMed: 9112437]
37. Staub O, Dho S, Henry P, Correa J, Ishikawa T, McGlade J, Rotin D. *Embo J* 1996;15:2371–2380. [PubMed: 8665844]
38. Goulet CC, Volk KA, Adams CM, Prince LS, Stokes JB, Snyder PM. *J Biol Chem* 1998;273:30012–30017. [PubMed: 9792722]
39. Scheffner M, Huibregtse JM, Howley PM. *Proc Natl Acad Sci USA* 1994;91:8797–8801. [PubMed: 8090726]
40. Nuber U, Schwarz S, Kaiser P, Schneider R, Scheffner M. *J Biol Chem* 1996;271:2795–2800. [PubMed: 8576257]
41. Kumar S, Kao WH, Howley PM. *J Biol Chem* 1997;272:13548–13554. [PubMed: 9153201]
42. Huang L, Kinnucan E, Wang G, Beaudenon S, Howley PM, Huibregtse JM, Pavletich NP. *Science* 1999;286:1321–1326. [PubMed: 10558980]
43. Nuber U, Scheffner M. *J Biol Chem* 1999;274:7576–7582. [PubMed: 10066826]
44. Saurin AJ, Borden KL, Boddy MN, Freemont PS. *Trends Biochem Sci* 1996;21:208–214. [PubMed: 8744354]
45. Miyake S, Lupper ML Jr, Druker B, Band H. *Proc Natl Acad Sci USA* 1998;95:7927–7932. [PubMed: 9653117]
46. Joazeiro CA, Wing SS, Huang H, Levenson JD, Hunter T, Liu YC. *Science* 1999;286:309–312. [PubMed: 10514377]
47. Levkowitz G, Waterman H, Ettenberg SA, Katz M, Tsygankov AY, Alroy I, Lavi S, Iwai K, Reiss Y, Ciechanover A, Lipkowitz S, Yarden Y. *Mol Cell* 1999;4:1029–1040. [PubMed: 10635327]
48. Yokouchi M, Kondo T, Houghton A, Bartkiewicz M, Horne WC, Zhang H, Yoshimura A, Baron R. *J Biol Chem* 1999;274:31707–31712. [PubMed: 10531381]
49. Waterman H, Levkowitz G, Alroy I, Yarden Y. *J Biol Chem* 1999;274:22151–22154. [PubMed: 10428778]
50. Blake TJ, Shapiro M, Morse HCd, Langdon WY. *Oncogene* 1991;6:653–657. [PubMed: 2030914]
51. Andoniou CE, Thien CB, Langdon WY. *Embo J* 1994;13:4515–4523. [PubMed: 7925293]
52. Zheng N, Wang P, Jeffrey PD, Pavletich NP. *Cell* 2000;102:533–539. [PubMed: 10966114]
53. Ulrich HD, Jentsch S. *Embo J* 2000;19:3388–3397. [PubMed: 10880451]
54. Duprez E, Saurin AJ, Desterro JM, Lallemand-Breitenbach V, Howe K, Boddy MN, Solomon E, de The H, Hay RT, Freemont PS. *J Cell Sci* 1999;112:381–393. [PubMed: 9885291]
55. Honda R, Tanaka H, Yasuda H. *FEBS Lett* 1997;420:25–27. [PubMed: 9450543]
56. Honda R, Yasuda H. *Embo J* 1999;18:22–27. [PubMed: 9878046]
57. Nasmyth K. *Science* 1996;274:1643–1645. [PubMed: 8984634]
58. King RW, Deshaies RJ, Peters J-M, Kirschner MW. *Science* 1996;274:1652–1659. [PubMed: 8939846]
59. Zachariae W, Schwab M, Nasmyth K, Seufert W. *Science* 1998;282:1721–1724. [PubMed: 9831566]
60. Yu H, Peters JM, King RW, Page AM, Hieter P, Kirschner MW. *Science* 1998;279:1219–1222. [PubMed: 9469815]
61. Peters JM. *Curr Opin Cell Biol* 1998;10:759–768. [PubMed: 9914180]
62. Skowrya D, Koepf DM, Kamura T, Conrad MN, Conaway RC, Conaway JW, Elledge SJ, Harper JW. *Science* 1999;284:662–665. [PubMed: 10213692]
63. Schwab M, Lutum AS, Seufert W. *Cell* 1997;90:683–693. [PubMed: 9288748]
64. Visintin R, Prinz S, Amon A. *Science* 1997;278:460–463. [PubMed: 9334304]
65. Fang G, Yu H, Kirschner MW. *Mol Cell* 1998;2:163–171. [PubMed: 9734353]
66. Kramer ER, Gieffers C, Holz G, Hengstschlager M, Peters JM. *Curr Biol* 1998;8:1207–1210. [PubMed: 9811605]
67. Sigrist S, Jacobs H, Stratmann R, Lehner CF. *Embo J* 1995;14:4827–4838. [PubMed: 7588612]
68. Zachariae W, Shevchenko A, Andrews PD, Ciosk R, Galova M, Stark MJ, Mann M, Nasmyth K. *Science* 1998;279:1216–1219. [PubMed: 9469814]

69. Levenson JD, Joazeiro CA, Page AM, Huang H, Hieter P, Hunter T. *Mol Biol Cell* 2000;11:2315–2325. [PubMed: 10888670]
70. Gmachl M, Gieffers C, Podtelejnikov AV, Mann M, Peters JM. *Proc Natl Acad Sci USA* 2000;97:8973–8978. [PubMed: 10922056]
71. Ohta T, Michel JJ, Schottelius AJ, Xiong Y. *Mol Cell* 1999;3:535–541. [PubMed: 10230407]
72. Zachariae W, Nasmyth K. *Genes Dev* 1999;13:2039–2058. [PubMed: 10465783]
73. Koepf DM, Harper JW, Elledge SJ. *Cell* 1999;97:431–434. [PubMed: 10338207]
74. Schwob E, Bohm T, Mendenhall MD, Nasmyth K. *Cell* 1994;79:233–244. [PubMed: 7954792]
75. Skowrya D, Craig KL, Tyers M, Elledge SJ, Harper JW. *Cell* 1997;91:209–219. [PubMed: 9346238]
76. Feldman RM, Correll CC, Kaplan KB, Deshaies RJ. *Cell* 1997;91:221–230. [PubMed: 9346239]
77. Zhang H, Kobayashi R, Galaktionov K, Beach D. *Cell* 1995;82:915–925. [PubMed: 7553852]
78. Chu S, DeRisi J, Eisen M, Mulholland J, Botstein D, Brown PO, Herskowitz I. *Science* 1998;282:699–705. [PubMed: 9784122]
79. Zhou P, Howley PM. *Mol Cell* 1998;2:571–580. [PubMed: 9844630]
80. Kamura T, Koepf DM, Conrad MN, Skowrya D, Moreland RJ, Iliopoulos O, Lane WS, Kaelin WG Jr, Elledge SJ, Conaway RC, Harper JW, Conaway JW. *Science* 1999;284:657–661. [PubMed: 10213691]
81. Tan P, Fuchs SY, Chen A, Wu K, Gomez C, Ronai Z, Pan ZQ. *Mol Cell* 1999;3:527–533. [PubMed: 10230406]
82. Seol JH, Feldman RM, Zachariae W, Shevchenko A, Correll CC, Lyapina S, Chi Y, Galova M, Claypool J, Sandmeyer S, Nasmyth K, Deshaies RJ. *Genes Dev* 1999;13:1614–1626. [PubMed: 10385629]
83. Stebbins CE, Kaelin WG Jr, Pavletich NP. *Science* 1999;284:455–461. [PubMed: 10205047]
84. Joazeiro CA, Weissman AM. *Cell* 2000;102:549–552. [PubMed: 11007473]
85. Tyers M, Jorgensen P. *Curr Opin Genet Dev* 2000;10:54–64. [PubMed: 10679394]
86. Loewe J, Stock D, Jap B, Zwickl P, Baumeister W, Huber R. *Science* 1995;268:533–539. [PubMed: 7725097]
87. Groll M, Ditzel L, Loewe J, Stock D, Bochtler M, Bartunik HD, Huber R. *Nature* 1997;386:463–471. [PubMed: 9087403]
88. Kopp F, Hendil KB, Dahlmann B, Kristensen P, Sobek A, Uerkevitz W. *Proc Natl Acad Sci USA* 1997;94:2939–2944. [PubMed: 9096325]
89. Glickman MH, Rubin DM, Coux O, Wefes I, Pfeifer G, Cjeka Z, Baumeister W, Fried VA, Finley D. *Cell* 1998;94:615–623. [PubMed: 9741626]
90. Braun BC, Glickman M, Kraft R, Dahlmann B, Kloetzel PM, Finley D, Schmidt M. *Nat Cell Biol* 1999;1:221–226. [PubMed: 10559920]
91. Orłowski M, Cardozo C, Hidalgo MC, Michaud C. *Biochemistry* 1991;30:5999–6005. [PubMed: 2043637]
92. Dahlmann B, Becher B, Sobek A, Ehlers C, Kopp F, Kuehn L. *Enzyme Protein* 1993;47:274–284. [PubMed: 7697125]
93. Shibatani T, Ward WF. *Arch Biochem Biophys* 1995;321:160–166. [PubMed: 7639516]
94. Ma CP, Slaughter CA, DeMartino GN. *J Biol Chem* 1992;267:10515–10523. [PubMed: 1587832]
95. Chu-Ping M, Vu JH, Proske RJ, Slaughter CA, DeMartino GN. *J Biol Chem* 1994;269:3539–3547. [PubMed: 8106396]
96. Hoffman L, Rechsteiner M. *J Biol Chem* 1994;269:16890–16895. [PubMed: 8207011]
97. Groll M, Bajorek M, Kohler A, Moroder L, Rubin DM, Huber R, Glickman MH, Finley D. *Nat Struct Biol* 2000;7:1062–1067. [PubMed: 11062564]
98. Yao Y, Huang L, Krutchinsky A, Wong ML, Standing KG, Burlingame AL, Wang CC. *J Biol Chem* 1999;274:33921–33930. [PubMed: 10567354]
99. Whitby FG, Masters EI, Kramer L, Knowlton JR, Yao Y, Wang CC, Hill CP. *Nature* 2000;408:115–120. [PubMed: 11081519]
100. Schechter I, Berger A. *Biochem Biophys Res Commun* 1967;27:157–162. [PubMed: 6035483]
101. Wilk S, Orłowski M. *J Neurochem* 1983;40:842–849. [PubMed: 6338156]

102. Cardozo C. *Enzyme Protein* 1993;47:296–305. [PubMed: 7697127]
103. Orłowski M, Cardozo C, Michaud C. *Biochemistry* 1993;32:1563–1572. [PubMed: 8431436]
104. Dick TP, Nussbaum AK, Deeg M, Heinemeyer W, Groll M, Schirle M, Keilholz W, Stevanovic S, Wolf DH, Huber R, Rammensee HG, Schild H. *J Biol Chem* 1998;273:25637–25646. [PubMed: 9748229]
105. McCormack TA, Cruikshank AA, Grenier L, Melandri FD, Nunes SL, Plamondon L, Stein RL, Dick LR. *Biochemistry* 1998;37:7792–7800. [PubMed: 9601040]
106. Cardozo C, Michaud C, Orłowski M. *Biochemistry* 1999;38:9768–9777. [PubMed: 10423257]
107. Hilt W, Enenkel C, Gruhler A, Singer T, Wolf DH. *J Biol Chem* 1993;268:3479–3486. [PubMed: 8381431]
108. Enenkel C, Lehmann H, Kipper J, Guckel R, Hilt W, Wolf DH. *FEBS Lett* 1994;341:193–196. [PubMed: 7907993]
109. Heinemeyer W, Gruhler A, Mohrle V, Mahe Y, Wolf DH. *J Biol Chem* 1993;268:5115–5120. [PubMed: 8383129]
110. Salzmann U, Kral S, Braun B, Standera S, Schmidt M, Kloetzel PM, Sijts A. *FEBS Lett* 1999;454:11–15. [PubMed: 10413086]
111. Orłowski M, Wilk S. *Arch Biochem Biophys* 2000;383:1–16. [PubMed: 11097171]
112. Seemüller E, Lupas A, Zuhl F, Zwickl P, Baumeister W. *FEBS Lett* 1995;359:173–178. [PubMed: 7867793]
113. Fenteany G, Standaert RF, Lane WS, Choi S, Corey EJ, Schreiber SL. *Science* 1995;268:726–731. [PubMed: 7732382]
114. Sin N, Kim K, Elofsson M, Meng L, Auth H, Kwok BHB, Crews CM. *Bioorg Med Chem Lett* 1999;9:2283–2288. [PubMed: 10465562]
115. Meng L, Mohan R, Kwok BHB, Elofsson M, Sin N, Crews CM. *Proc Natl Acad Sci USA* 1999;96:10403–10408. [PubMed: 10468620]
116. Groll M, Kim KB, Huber R, Crews CM. *J Am Chem Soc* 2000;122:1237–1238.
117. Brannigan JA, Dodson G, Duggleby HJ, Moody PC, Smith JL, Tomchick DR, Murzin AG. *Nature* 1995;378:416–419. [PubMed: 7477383]
118. Duggleby HJ, Tolley SP, Hill CP, Dodson EJ, Dodson G, Moody PC. *Nature* 1995;373:264–268. [PubMed: 7816145]
119. Oinonen C, Tikkanen R, Rouvinen J, Peltonen L. *Nat Struct Biol* 1995;2:1102–1108. [PubMed: 8846222]
120. Seemuüller E, Lupas A, Stock D, Lowe J, Huber R, Baumeister W. *Science* 1995;268:579–582. [PubMed: 7725107]
121. Frentzel S, Pesold-Hurt B, Seelig A, Kloetzel PM. *J Mol Biol* 1994;236:975–981. [PubMed: 8120905]
122. Yang Y, Fruh K, Ahn K, Peterson PA. *J Biol Chem* 1995;270:27687–27694. [PubMed: 7499235]
123. Tamura T, Tanaka K, Kumatori A, Yamada F, Tsurumi C, Fujiwara T, Ichihara A, Tokunaga F, Aruga R, Iwanaga S. *FEBS Lett* 1990;264:91–94. [PubMed: 2338147]
124. Tamura T, Lee DH, Osaka F, Fujiwara T, Shin S, Chung CH, Tanaka K, Ichihara A. *Biochim Biophys Acta* 1991;1089:95–102. [PubMed: 2025653]
125. Heinemeyer W, Kleinschmidt JA, Saidowsky J, Escher C, Wolf DH. *Embo J* 1991;10:555–562. [PubMed: 2001673]
126. Evans T, Rosenthal ET, Youngblom J, Distel D, Hunt T. *Cell* 1983;33:389–396. [PubMed: 6134587]
127. Swenson KI, Farrell KM, Ruderman JV. *Cell* 1986;47:861–870. [PubMed: 2946420]
128. Glotzer M, Murray AW, Kirschner MW. *Nature* 1991;349:132–138. [PubMed: 1846030]
129. Lohrum MA, Vousden KH. *Trends Cell Biol* 2000;10:197–202. [PubMed: 10754563]
130. Deshaies RJ. *Curr Opin Genet Dev* 1997;7:7–16. [PubMed: 9024629]
131. Caspari T. *Curr Biol* 2000;10:R315–R317. [PubMed: 10801407]
132. Ciechanover A, DiGiuseppe JA, Bercovich B, Orian A, Richter JD, Schwartz AL, Brodeur GM. *Proc Natl Acad Sci USA* 1991;88:139–143. [PubMed: 1846034]
133. Maki CG, Huijbregtse JM, Howley PM. *Cancer Res* 1996;56:2649–2654. [PubMed: 8653711]

134. Haupt Y, Maya R, Kazaz A, Oren M. *Nature* 1997;387:296–299. [PubMed: 9153395]
135. Kubbutat MH, Jones SN, Vousden KH. *Nature* 1997;387:299–303. [PubMed: 9153396]
136. Fang S, Jensen JP, Ludwig RL, Vousden KH, Weissman AM. *J Biol Chem* 2000;275:8945–8951. [PubMed: 10722742]
137. Honda R, Yasuda H. *Oncogene* 2000;19:1473–1476. [PubMed: 10723139]
138. Prives C. *Cell* 1998;95:5–8. [PubMed: 9778240]
139. Shieh SY, Ikeda M, Taya Y, Prives C. *Cell* 1997;91:325–334. [PubMed: 9363941]
140. Unger T, Juven-Gershon T, Moallem E, Berger M, Vogt Sionov R, Lozano G, Oren M, Haupt Y. *Embo J* 1999;18:1805–1814. [PubMed: 10202144]
141. Ashcroft M, Vousden KH. *Oncogene* 1999;18:7637–7643. [PubMed: 10618703]
142. Mayo LD, Turchi JJ, Berberich SJ. *Cancer Res* 1997;57:5013–5016. [PubMed: 9371494]
143. Khosravi R, Maya R, Gottlieb T, Oren M, Shiloh Y, Shkedy D. *Proc Natl Acad Sci USA* 1999;96:14973–14977. [PubMed: 10611322]
144. Sen R, Baltimore D. *Cell* 1986;47:921–928. [PubMed: 3096580]
145. Baeuerle PA, Henkel T. *Annu Rev Immunol* 1994;12:141–179. [PubMed: 8011280]
146. Baeuerle PA, Baltimore D. *Cell* 1996;87:13–20. [PubMed: 8858144]
147. Baldwin AS Jr. *Annu Rev Immunol* 1996;14:649–683. [PubMed: 8717528]
148. Barnes PJ, Karin M. *N Engl J Med* 1997;336:1066–1071. [PubMed: 9091804]
149. Ghosh S, May MJ, Kopp EB. *Annu Rev Immunol* 1998;16:225–260. [PubMed: 9597130]
150. Karin M, Ben-Neriah Y. *Annu Rev Immunol* 2000;18:621–663. [PubMed: 10837071]
151. Stancovski I, Baltimore D. *Cell* 1997;91:299–302. [PubMed: 9363938]
152. Maniatis T. *Science* 1997;278:818–819. [PubMed: 9381193]
153. Yaron A, Hatzubai A, Davis M, Lavon I, Amit S, Manning AM, Andersen JS, Mann M, Mercurio F, Ben-Neriah Y. *Nature* 1998;396:590–594. [PubMed: 9859996]
154. Spencer E, Jiang J, Chen ZJ. *Genes Dev* 1999;13:284–294. [PubMed: 9990853]
155. Winston JT, Strack P, Beer-Romero P, Chu CY, Elledge SJ, Harper JW. *Genes Dev* 1999;13:270–283. [PubMed: 9990852]
156. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. *Cell* 1994;78:773–785. [PubMed: 8087845]
157. Alkalay I, Yaron A, Hatzubai A, Orian A, Ciechanover A, Ben-Neriah Y. *Proc Natl Acad Sci USA* 1995;92:10599–10603. [PubMed: 7479848]
158. Chen Z, Hagler J, Palombella VJ, Melandri F, Scherer D, Ballard D, Maniatis T. *Genes Dev* 1995;9:1586–1597. [PubMed: 7628694]
159. Fan CM, Maniatis T. *Nature* 1991;354:395–398. [PubMed: 1956402]
160. Orian A, Whiteside S, Israel A, Stancovski I, Schwartz AL, Ciechanover A. *J Biol Chem* 1995;270:21707–21714. [PubMed: 7665588]
161. Sears C, Olesen J, Rubin D, Finley D, Maniatis T. *J Biol Chem* 1998;273:1409–1419. [PubMed: 9430676]
162. Coux O, Goldberg AL. *J Biol Chem* 1998;273:8820–8828. [PubMed: 9535861]
163. Rice NR, MacKichan ML, Israel A. *Cell* 1992;71:243–253. [PubMed: 1423592]
164. Mercurio F, DiDonato JA, Rosette C, Karin M. *Genes Dev* 1993;7:705–718. [PubMed: 8458581]
165. Naumann M, Wulczyn FG, Scheidereit C. *Embo J* 1993;12:213–222. [PubMed: 8428580]
166. Orian A, Gonen H, Bercovich B, Fajerman I, Eytan E, Israel A, Mercurio F, Iwai K, Schwartz AL, Ciechanover A. *Embo J* 2000;19:2580–2591. [PubMed: 10835356]
167. Heissmeyer V, Krappmann D, Wulczyn FG, Scheidereit C. *Embo J* 1999;18:4766–4778. [PubMed: 10469655]
168. Lin L, DeMartino GN, Greene WC. *Cell* 1998;92:819–828. [PubMed: 9529257]
169. Lin L, DeMartino GN, Greene WC. *Embo J* 2000;19:4712–4722. [PubMed: 10970863]
170. Pamer E, Cresswell P. *Annu Rev Immunol* 1998;16:323–358. [PubMed: 9597133]
171. Rock KL, Goldberg AL. *Ann Rev Immunol* 1999;17:739–779. [PubMed: 10358773]

172. Michalek MT, Grant EP, Gramm C, Goldberg AL, Rock KL. *Nature* 1993;363:552–554. [PubMed: 8389422]
173. Cox JH, Galardy P, Bennink JR, Yewdell JW. *J Immunol* 1995;154:511–519. [PubMed: 7814864]
174. Michalek MT, Grant EP, Rock KL. *J Immunol* 1996;157:617–624. [PubMed: 8752909]
175. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, Hwang D, Goldberg AL. *Cell* 1994;78:761–771. [PubMed: 8087844]
176. Harding CV, France J, Song R, Farah JM, Chatterjee S, Iqbal M, Siman R. *J Immunol* 1995;155:1767–1775. [PubMed: 7636233]
177. Hughes EA, Ortmann B, Surman M, Cresswell P. *J Exp Med* 1996;183:1569–1578. [PubMed: 8666915]
178. Craiu A, Gaczynska M, Akopian T, Gramm CF, Fenteany G, Goldberg AL, Rock KL. *J Biol Chem* 1997;272:13437–13445. [PubMed: 9148969]
179. Cerundolo V, Benham A, Braud V, Mukherjee S, Gould K, Macino B, Neefjes J, Townsend A. *Eur J Immunol* 1997;27:336–341. [PubMed: 9022037]
180. Putterman D, Pepinsky RB, Vogt VM. *Virology* 1990;176:633–637. [PubMed: 2161153]
181. Ott DE, Coren LV, Copeland TD, Kane BP, Johnson DG, Sowder RC 2nd, Yoshinaka Y, Oroszlan S, Arthur LO, Henderson LE. *J Virol* 1998;72:2962–2968. [PubMed: 9525617]
182. Strack B, Calistri A, Accola MA, Palu G, Gottlinger HG. *Proc Natl Acad Sci USA* 2000;97:13063–13068. [PubMed: 11087860]
183. Patnaik A, Chau V, Wills JW. *Proc Natl Acad Sci USA* 2000;97:13069–13074. [PubMed: 11087861]
184. Schubert U, Ott DE, Chertova EN, Welker R, Tessmer U, Princiotta MF, Bennink JR, Krausslich HG, Yewdell JW. *Proc Natl Acad Sci USA* 2000;97:13057–13062. [PubMed: 11087859]
185. Wiertz EJ, Tortorella D, Bogyo M, Yu J, Mothes W, Jones TR, Rapoport TA, Ploegh HL. *Nature* 1996;384:432–438. [PubMed: 8945469]
186. Wiertz EJ, Jones TR, Sun L, Bogyo M, Geuze HJ, Ploegh HL. *Cell* 1996;84:769–779. [PubMed: 8625414]
187. Angelman H. *Dev Med Child Neurol* 1965;7:681–688.
188. Mann MR, Bartolomei MS. *Hum Mol Genet* 1999;8:1867–1873. [PubMed: 10469839]
189. Williams CA, Angelman H, Clayton-Smith J, Driscoll DJ, Hendrickson JE, Knoll JH, Magenis RE, Schinzel A, Wagstaff J, Whidden EM, et al. *Am J Med Genet* 1995;56:237–238. [PubMed: 7625452]
190. Kishino T, Lalonde M, Wagstaff J. *Nat Genet* 1997;15:70–73. [PubMed: 8988171]
191. Matsuura T, Sutcliffe JS, Fang P, Galjaard RJ, Jiang YH, Benton CS, Rommens JM, Beaudet AL. *Nat Genet* 1997;15:74–77. [PubMed: 8988172]
192. Liddle G, Bledsoe T, Coppage W. *Trans Assoc Am Phys* 1963;76:199–213.
193. Shimkets RA, Warnock DG, Bositis CM, Nelson-Williams C, Hansson JH, Schambelan M, Gill JR Jr, Ulick S, Milora RV, Findling JW, et al. *Cell* 1994;79:407–414. [PubMed: 7954808]
194. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. *Cell* 1990;63:1129–1136. [PubMed: 2175676]
195. Huibregtse JM, Scheffner M, Howley PM. *Mol Cell Biol* 1993;13:775–784. [PubMed: 8380895]
196. Talis AL, Huibregtse JM, Howley PM. *J Biol Chem* 1998;273:6439–6445. [PubMed: 9497376]
197. Gross-Mesilaty S, Reinstein E, Bercovich B, Tobias KE, Schwartz AL, Kahana C, Ciechanover A. *Proc Natl Acad Sci USA* 1998;95:8058–8063. [PubMed: 9653139]
198. Kao WH, Beaudenon SL, Talis AL, Huibregtse JM, Howley PM. *J Virol* 2000;74:6408–6417. [PubMed: 10864652]
199. Kinzler KW, Vogelstein B. *Cell* 1996;87:159–170. [PubMed: 8861899]
200. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. *Embo J* 1997;16:3797–3804. [PubMed: 9233789]
201. Behrens J, Jerchow BA, Wurtele M, Grimm J, Asbrand C, Wirtz R, Kuhl M, Wedlich D, Birchmeier W. *Science* 1998;280:596–599. [PubMed: 9554852]
202. Ikeda S, Kishida M, Matsuura Y, Usui H, Kikuchi A. *Oncogene* 2000;19:537–545. [PubMed: 10698523]

203. Munemitsu S, Albert I, Souza B, Rubinfeld B, Polakis P. *Proc Natl Acad Sci USA* 1995;92:3046–3050. [PubMed: 7708772]
204. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW. *Science* 1997;275:1787–1790. [PubMed: 9065402]
205. Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, Vogelstein B, Clevers H. *Science* 1997;275:1784–1787. [PubMed: 9065401]
206. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW. *Science* 1998;281:1509–1512. [PubMed: 9727977]
207. Tetsu O, McCormick F. *Nature* 1999;398:422–426. [PubMed: 10201372]
208. Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E, Polakis P. *Science* 1997;275:1790–1792. [PubMed: 9065403]
209. Hart M, Concordet JP, Lassot I, Albert I, del los Santos R, Durand H, Perret C, Rubinfeld B, Margottin F, Benarous R, Polakis P. *Curr Biol* 1999;9:207–210. [PubMed: 10074433]
210. Latres E, Chiaur DS, Pagano M. *Oncogene* 1999;18:849–854. [PubMed: 10023660]
211. Mori H, Kondo J, Ihara Y. *Science* 1987;235:1641–1644. [PubMed: 3029875]
212. Perry G, Friedman R, Shaw G, Chau V. *Proc Natl Acad Sci USA* 1987;84:3033–3036. [PubMed: 3033674]
213. van Leeuwen FW, de Kleijn DP, van den Hurk HH, Neubauer A, Sonnemans MA, Sluijs JA, Koycu S, Ramdjielal RDJ, Salehi A, Martens GJM, Grosveld FG, Peter J, Burbach H, Hol EM. *Science* 1998;279:242–247. [PubMed: 9422699]
214. Checler F, da Costa CA, Ancolio K, Chevallier N, Lopez-Perez E, Marambaud P. *Biochim Biophys Acta* 2000;1502:133–138. [PubMed: 10899438]
215. Checler FJ. *Neurochem* 1995;65:1431–1444.
216. Marambaud P, Ancolio K, Lopez-Perez E, Checler F. *Mol Med* 1998;4:147–157. [PubMed: 9562973]
217. Kim TW, Pettingell WH, Hallmark OG, Moir RD, Wasco W, Tanzi RE. *J Biol Chem* 1997;272:11006–11010. [PubMed: 9110991]
218. Marambaud P, Alves da Costa C, Ancolio K, Checler F. *Biochem Biophys Res Commun* 1998;252:134–138. [PubMed: 9813158]
219. Orłowski M. *Biochemistry* 1990;29:10289–10297. [PubMed: 2175651]
220. Figueiredo-Pereira ME, Banik N, Wilk S. *J Neurochem* 1994;62:1989–1994. [PubMed: 8158145]
221. Wilk S, Figueiredo-Pereira ME. *Enzyme Protein* 1993;47:306–313. [PubMed: 7697128]
222. Vinitzky A, Cardozo C, Sepp-Lorenzino L, Michaud C, Orłowski M. *J Biol Chem* 1994;269:29860–29866. [PubMed: 7961980]
223. Lynas JF, Harriott P, Healy A, McKervey MA, Walker B. *Bioorg Med Chem Lett* 1998;8:373–378. [PubMed: 9871688]
224. Iqbal M, Chatterjee S, Kauer JC, Mallamo JP, Messina PA, Reiboldt A, Siman R. *Bioorg Med Chem Lett* 1996;6:287–290.
225. Lum RT, Nelson MG, Joly A, Horsma AG, Lee G, Meyer SM, Wick MM, Schow SR. *Bioorg Med Chem Lett* 1998;8:209–214. [PubMed: 9871656]
226. Chatterjee S, Dunn D, Mallya S, Ator MA. *Bioorg Med Chem Lett* 1999;9:2603–2606. [PubMed: 10498217]
227. Spaltenstein A, Leban JJ, Huang JJ, Reinhardt KR, Viveros OH, Sigafos J, Crouch R. *Tet Lett* 1996;37:1343–1346.
228. Bogyo M, Shin S, McMaster JS, Ploegh HL. *Chem Biol* 1998;5:307–320. [PubMed: 9653549]
229. Palmer JT, Rasnick D, Klaus JL, Bromme D. *J Med Chem* 1995;38:3193–3196. [PubMed: 7650671]
230. Bromme D, Klaus JL, Okamoto K, Rasnick D, Palmer JT. *Biochem J* 1996;315:85–89. [PubMed: 8670136]
231. Glas R, Bogyo M, McMaster JS, Gaczynska M, Ploegh HL. *Nature* 1998;392:618–622. [PubMed: 9560160]
232. Bogyo M, McMaster JS, Gaczynska M, Tortorella D, Goldberg AL, Ploegh H. *Proc Natl Acad Sci USA* 1997;94:6629–6634. [PubMed: 9192616]

233. McCormack T, Baumeister W, Grenier L, Moomaw C, Plamondon L, Pramanik B, Slaughter C, Soucy F, Stein R, Zuhl F, Dick L. *J Biol Chem* 1997;272:26103–26109. [PubMed: 9334174]
234. Adams J, Behnke M, Chen S, Cruickshank AA, Dick LR, Grenier L, Klunder JM, Ma YT, Plamondon L, Stein RL. *Bioorg Med. Chem Lett* 1998;8:333–338. [PubMed: 9871680]
235. Elofsson M, Splittergerber U, Myung J, Mohan R, Crews CM. *Chem Biol* 1999;6:811–822. [PubMed: 10574782]
236. Palombella VJ, Conner EM, Fuseler JW, Destree A, Davis JM, Laroux FS, Wolf RE, Huang J, Brand S, Elliott PJ, Lazarus D, McCormack T, Parent L, Stein R, Adams J, Grisham MB. *Proc Natl Acad Sci USA* 1998;95:15671–15676. [PubMed: 9861028]
237. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ. *Cancer Res* 1999;59:2615–2622. [PubMed: 10363983]
238. Drexler HC. *Proc Natl Acad Sci USA* 1997;94:855–860. [PubMed: 9023346]
239. Lopes UG, Erhardt P, Yao R, Cooper GM. *J Biol Chem* 1997;272:12893–12896. [PubMed: 9148891]
240. Chandra J, Niemer I, Gilbreath J, Kliche KO, Andreeff M, Freireich EJ, Keating M, McConkey DJ. *Blood* 1998;92:4220–4229. [PubMed: 9834227]
241. Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J. *Clin Cancer Res* 1999;5:2638–2645. [PubMed: 10499643]
242. Adams J, Palombella VJ, Elliott PJ. *Invest New Drugs* 2000;18:109–121. [PubMed: 10857991]
243. Omura S, Fujimoto T, Otoguro K, Matsuzaki K, Moriguchi R, Tanaka H, Sasaki Y. *J Antibiot (Tokyo)* 1991;44:113–116. [PubMed: 1848215]
244. Omura S, Matsuzaki K, Fujimoto T, Kosuge K, Furuya T, Fujita S, Nakagawa A. *J Antibiot (Tokyo)* 1991;44:117–118. [PubMed: 2001981]
245. Fenteany G, Standaert RF, Reichard GA, Corey EJ, Schreiber SL. *Proc Natl Acad Sci USA* 1994;91:3358–3362. [PubMed: 8159752]
246. Katagiri M, Hayashi M, Matsuzaki K, Tanaka H, Omura S. *J Antibiot (Tokyo)* 1995;48:344–346. [PubMed: 7775277]
247. Dick LR, Cruickshank AA, Grenier L, Melandri FD, Nunes SL, Stein RL. *J Biol Chem* 1996;271:7273–7276. [PubMed: 8631740]
248. Ostrowska H, Wojcik C, Omura S, Worowski K. *Biochem Biophys Res Commun* 1997;234:729–732. [PubMed: 9175783]
249. Geier E, Pfeifer G, Wilm M, Lucchiari-Hartz M, Baumeister W, Eichmann K, Niedermann G. *Science* 1999;283:978–981. [PubMed: 9974389]
250. Ostrowska H, Wojcik C, Wilk S, Omura S, Kozlowski L, Stoklosa T, Worowski K, Radziwon P. *Int J Biochem Cell Biol* 2000;32:747–757. [PubMed: 10856705]
251. Corey EJ, Li W. *Chem Pharm Bull* 1999;47:1–10. [PubMed: 9987821]
252. Hanada M, Sugawara K, Kaneta K, Toda S, Nishiyama Y, Tomita K, Yamamoto H, Konishi M, Oki T. *J. Antibiotics* 1992;45:1746–1752. [PubMed: 1468981]
253. Sugawara K, Hatori M, Nishiyama Y, Tomita K, Kamei H, Konishi M, Oki T. *J. Antibiotics* 1990;43:8–18. [PubMed: 2106503]
254. Meng L, Kwok BHB, Sin N, Crews CM. *Cancer Research* 1999;59:2798–2801. [PubMed: 10383134]
255. Koguchi Y, Kohno J, Suzuki S, Nishio M, Takahashi K, Ohnuki T, Komatsubara S. *J Antibiot (Tokyo)* 2000;53:63–65. [PubMed: 10724010]
256. Koguchi Y, Nishio M, Suzuki S, Takahashi K, Ohnuki T, Komatsubara S. *J Antibiot (Tokyo)* 2000;53:967–972. [PubMed: 11099231]
257. Kohno J, Koguchi Y, Nishio M, Nakao K, Kuroda M, Shimizu R, Ohnuki T, Komatsubara S. *J Org Chem* 2000;65:990–995. [PubMed: 10814045]
258. Koguchi Y, Kohno J, Nishio M, Takahashi K, Okuda T, Ohnuki T, Komatsubara S. *J Antibiot (Tokyo)* 2000;53:105–109. [PubMed: 10805568]
259. Pahl HL, Krauss B, Schulze-Osthoff K, Decker T, Traenckner EB, Vogt M, Myers C, Parks T, Warring P, Muhlbacher A, Czernilofsky AP, Baeuerle PA. *J Exp Med* 1996;183:1829–1840. [PubMed: 8666939]

260. Kroll M, Arenzana-Seisdedos F, Bachelier F, Thomas D, Friguet B, Conconi M. *Chem Biol* 1999;6:689–698. [PubMed: 10508680]
261. Loidl G, Groll M, Musiol H-J, Ditzel L, Huber R, Moroder L. *Chem Biol* 1999;6:197–204. [PubMed: 10099130]
262. Loidl G, Groll M, Musiol H-J, Huber R, Moroder L. *Proc Natl Acad Sci USA* 1999;96:5418–5422. [PubMed: 10318898]
263. Okada K, Wangpoengtrakul C, Osawa T, Toyokuni S, Tanaka K, Uchida K. *J Biol Chem* 1999;274:23787–23793. [PubMed: 10446139]
264. Myung J, Kim KB, Lindsten K, Dantuma NP, Crews CM. *Molecular Cell* 2001;7:411–420. [PubMed: 11239469]


## Biographies

**Jayhyuk Myung** received his PhD in biochemistry in 1994 after doctoral training in the laboratory of Dr William P. Jencks at Brandeis University. After postdoctoral training with Dr Ira S. Mellman at Yale School of Medicine, studying the molecular mechanism of polarized vesicle traffic in the MDCK cells, he is currently involved in examining the mechanism of the 20S proteasome using a “chemical knockout” approach in the laboratory of Dr Craig M. Crews at Yale University. He received a National Research Service Award (NIH) and an Anderson Fellowship (Yale University). His research interests focus on understanding complex intracellular signaling networks by exploring the nature of biologically active natural products.


**Kyung Bo Kim** graduated from Yonsei University in 1988 and obtained his MS with Dr Dong Han Kim from the Pohang University of Science and Technology in 1991. After completing his PhD in the field of sugar nucleotide chemistry under the supervision of Dr Edward Behrman at the Ohio State University in 1997, he is currently conducting postdoctoral studies in the laboratory of Dr Craig Crews. His research interests focus on the development of novel molecular probes to unravel complex signaling pathways and the identification novel potential drug targets.

**Craig M. Crews** graduated from the University of Virginia in 1986 and then studied for a year in Tübingen, Germany, as a DAAD Fellow. He received his PhD from Harvard University in 1993. After completing his postdoctoral training with Stuart Schreiber at Harvard University, he joined the faculty at Yale University where he is currently Associate Professor of Molecular, Cellular, and Developmental Biology as well as of Pharmacology. His research interests lie at the interface of chemistry and biology. In particular, his laboratory uses biologically active natural products to identify and validate novel drug targets.







**Figure 1.**  
The proposed mechanism for the proteolysis catalyzed by the 20S proteasome.




**Figure 2.**  
Proteasome inhibitor family of synthetic peptide aldehydes.




**Figure 3.** The proposed mechanism for the inhibition of the 20S proteasome by the peptide aldehyde.





**Figure 4.**  
A family of reversible synthetic proteasome inhibitors.




**Figure 5.** (a) A family of irreversible synthetic proteasome inhibitors. (b) The proposed mechanism for the inhibition of the 20S proteasome by NLVS.



**Figure 6.** A synthetic peptide boronic acid inhibitor (PS-341) and its proposed inhibition mechanism.




**Figure 7.** Natural product Lactacystin, its active component, *clasto*-lactacystin  $\beta$ -lactone, and its proposed inhibition mechanism.




**Figure 8.**  
A family of natural product peptide  $\alpha',\beta'$ -epoxyketone-based proteasome inhibitors.






**Figure 9.**  
The proposed morpholino adduct formation mechanism by epoxomicin.





TMC-95	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	R <sub>4</sub>
A	H	OH	CH <sub>3</sub>	H
B	H	OH	H	CH <sub>3</sub>
C	OH	H	CH <sub>3</sub>	R <sub>4</sub>
D	OH	H	H	CH <sub>3</sub>


(24)




Gliotoxin (25) (active)

Reduced gliotoxin (26)  
(inactive)


**Figure 10.**  
Natural product proteasome inhibitors with unusual scaffolds.




(27)



(28)



HNE(4-hydroxy-2-nonenal) (29)



YU 102 (30)

**Figure 11.**  
Subunit-specific proteasome inhibitors.